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A B S T R A C T
Background
A possible strategy for increasing smoking cessation rates could be to provide smokers with feedback on the current or potential future
biomedical eHects of smoking using, for example, measurement of exhaled carbon monoxide (CO), lung function, or genetic susceptibility
to lung cancer or other diseases.
Objectives
The main objective was to determine the eHicacy of providing smokers with feedback on their exhaled CO measurement, spirometry
results, atherosclerotic plaque imaging, and genetic susceptibility to smoking-related diseases in helping them to quit smoking.
Search methods
For the most recent update, we searched the Cochrane Tobacco Addiction Group Specialized Register in March 2018 and ClinicalTrials.gov
and the WHO ICTRP in September 2018 for studies added since the last update in 2012.
Selection criteria
Inclusion criteria for the review were: a randomised controlled trial design; participants being current smokers; interventions based on
a biomedical test to increase smoking cessation rates; control groups receiving all other components of intervention; and an outcome of
smoking cessation rate at least six months aNer the start of the intervention.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We expressed results as a risk ratio (RR) for smoking cessation with
95% confidence intervals (CI). Where appropriate, we pooled studies using a Mantel-Haenszel random-eHects method.
Main results
We included 20 trials using a variety of biomedical tests interventions; one trial included two interventions, for a total of 21 interventions.
We included a total of 9262 participants, all of whom were adult smokers. All studies included both men and women adult smokers at
diHerent stages of change and motivation for smoking cessation. We judged all but three studies to be at high or unclear risk of bias
in at least one domain. We pooled trials in three categories according to the type of biofeedback provided: feedback on risk exposure
(five studies); feedback on smoking-related disease risk (five studies); and feedback on smoking-related harm (11 studies). There was no
evidence of increased cessation rates from feedback on risk exposure, consisting mainly of feedback on CO measurement, in five pooled
trials (RR 1.00, 95% CI 0.83 to 1.21; I2 = 0%; n = 2368). Feedback on smoking-related disease risk, including four studies testing feedback
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on genetic markers for cancer risk and one study with feedback on genetic markers for risk of Crohn's disease, did not show a benefit in
smoking cessation (RR 0.80, 95% CI 0.63 to 1.01; I2 = 0%; n = 2064). Feedback on smoking-related harm, including nine studies testing
spirometry with or without feedback on lung age and two studies on feedback on carotid ultrasound, also did not show a benefit (RR
1.26, 95% CI 0.99 to 1.61; I2 = 34%; n = 3314). Only one study directly compared multiple forms of measurement with a single form of
measurement, and did not detect a significant diHerence in eHect between measurement of CO plus genetic susceptibility to lung cancer
and measurement of CO only (RR 0.82, 95% CI 0.43 to 1.56; n = 189).
Authors' conclusions
There is little evidence about the eHects of biomedical risk assessment as an aid for smoking cessation. The most promising results relate to
spirometry and carotid ultrasound, where moderate-certainty evidence, limited by imprecision and risk of bias, did not detect a statistically
significant benefit, but confidence intervals very narrowly missed one, and the point estimate favoured the intervention. A sensitivity
analysis removing those studies at high risk of bias did detect a benefit. Moderate-certainty evidence limited by risk of bias did not detect
an eHect of feedback on smoking exposure by CO monitoring. Low-certainty evidence, limited by risk of bias and imprecision, did not
detect a benefit from feedback on smoking-related risk by genetic marker testing. There is insuHicient evidence with which to evaluate the
hypothesis that multiple types of assessment are more eHective than single forms of assessment.
P L A I N   L A N G U A G E   S U M M A R Y
Does giving people feedback on the e4ects of smoking on their body help them quit smoking?
Background
Biomedical risk assessment is the process of giving people feedback on the eHects of smoking on their body. The physical eHects of smoking
can be assessed using various measurements, and some people think this could be used as a tool to encourage people to quit smoking.
We reviewed the evidence about whether giving adult smokers feedback on the eHects of smoking on their body helps them quit smoking.
Study characteristics
This review includes 20 studies using a variety of measurements. One study included two measurements, for a total of 21 measurements
assessed. The main feedback measurements we assessed were the level of carbon monoxide in people's breath (a sign of current smoking),
measures of lung function (a sign of lung damage from smoking), genetic tests to provide individual risk of cancer, and ultrasound of major
arteries in the neck to measure the amount of plaque (a risk factor for stroke). We grouped studies into three categories according to
the type of feedback people were given: feedback on exposure to smoking (five studies); feedback on a person's risk for smoking-related
diseases (five studies); and feedback on the harms of smoking (11 studies). The studies included a total of 9262 people. All participants were
adult smokers, and both men and women were included (although one study performed in a clinic for army veterans included only 4%
women). Most studies were conducted in general practices or ambulatory clinics. All of the studies lasted at least six months. The reported
evidence is current as of March 2018.
Key results
We did not find evidence that giving smokers feedback on their smoking exposure, their genetic risk of smoking-related disease, or the
eHects of smoking on their body helps them quit smoking. The most promising results were for giving people feedback on the harm
smoking does to their bodies. The studies did not report on harms or side eHects of providing feedback. However, given the nature of the
measurements (lung or blood tests), we would expect the risk of harms to be low.
Certainty of evidence
Because of problems with the way some of the studies were conducted, we think that further research is likely to change our conclusions.
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Summary of findings for the main comparison.   Biomedical risk assessment compared with standard care or minimal intervention for smoking
cessation
Biomedical risk assessment compared with standard care or minimal intervention for smoking cessation
Patient or population: people who smoke
Setting: mixed
Intervention: biomedical risk assessment
Comparison: standard care or minimal intervention
Anticipated absolute effects* (95% CI)Outcomes
Risk with control Risk with biomedical risk as-
sessment
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Study populationFeedback on smoking exposure
Smoking cessation at longest follow-up over 6 months 153 per 1000 153 per 1000
(127 to 185)
RR 1.00
(0.83 to 1.21)
2368
(5 studies)
⊕⊕⊕⊝1
moderate
Study populationFeedback on smoking-related risk
Smoking cessation at longest follow-up over 6 months 130 per 1000 104 per 1000
(82 to 131)
RR 0.80
(0.63 to 1.01)
2064
(5 studies)
⊕⊕⊝⊝1,2
low
Study populationFeedback on smoking-related harm
Smoking cessation at longest follow-up over 6 months 117 per 1000 147 per 1000
(116 to 188)
RR 1.26
(0.99 to 1.61)
3314
(11 studies)
⊕⊕⊕⊝3
moderate
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
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Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1Downgraded one level for risk of bias: three out of five studies at high risk of bias, and remaining studies at unclear risk of bias.
2Downgraded one level for imprecision: fewer than 300 events.
3Downgraded one level for imprecision and risk of bias: sensitivity analysis removing studies at high risk of bias produced a statistically significant benefit.
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B A C K G R O U N D
Description of the condition
Smoking is the leading cause of preventable mortality and
morbidity in industrialised countries (CDC 2014; Phillips 1995;
Sargeant 2001; Yach 2000), and increasingly the smoking epidemic
is aHecting low- and middle-income countries. This is particularly
true for vascular and respiratory diseases, as well as for cancer
(DHHS 2004; Doll 2004; Thun 2013). Stopping smoking prolongs life
and reduces morbidity (DHHS 1990; Jha 2013). Despite increasing
scientific knowledge about health hazards due to cigarette
consumption, there is still an increase in prevalence in many
countries (Bilano 2015). The gap between knowledge and smoking
cessation has been attributed, in part, to smokers' underestimation
of their personal risks of smoking-related illness (Krosnick 2017;
Lerman 1993; Romer 2001). Although many smokers who are
successful in quitting do so on their own (Livingstone-Banks 2019;
Schwartz 1987), an increasing proportion use specific aids to
support a quit attempt.
Description of the intervention
Evidence is growing on how to help smokers to quit (Fiore 2008;
Hartmann-Boyce 2018; Kottke 1988; Lancaster 2017; Stead 2013;
West 2000). Interventions that have been shown to help quitting
smoking include individual or group counselling, pharmacological
therapies, and possibly some forms of self-help materials. Another
possible strategy for increasing quit rates is to provide feedback on
the physical eHects of smoking by physiological measurements. We
can conceptually distinguish, in this respect, three diHerent types
of feedback: the first one explores biomarkers of smoking exposure
(cotinine, carbon monoxide); the second one gives information
on smoking-related disease risk (e.g. lung cancer susceptibility
according to cytochrome P450 2D6 (CYP2D6) genotyping) (Audrain
1997); and the third one depicts smoking-related harm (e.g.
atherosclerotic plaque, impaired lung function) (Buist 2002).
How the intervention might work
The rationale for such interventions is to provide personalised
motivational feedback to promote risk awareness and to accelerate
smoking behaviour change (Curry 1993; Miller 1991). Recognition
of personal susceptibility to the adverse eHects of smoking may be
an important step in the pathway to smoking cessation (McClure
2001; Weinberger 1981; Young 2010). Indeed, most theories related
to health behaviour changes (e.g. self-determination theory, theory
of planned behaviour, health belief model, transtheoretical model,
social cognitive theory, social ecological model, common-sense
model) have in common that they recognise an important role to
the person's understanding of the potential negative consequences
of a given behaviour (Hale 2007; Joseph 2016).
Why it is important to do this review
Individual studies have produced conflicting data on the eHect
of physiological feedback (Bovet 2002; BuHels 2006; Lerman
1993; McBride 2000; Parkes 2008; Rodondi 2012). This review
systematically examined data on smoking cessation rates from
randomised controlled trials using feedback on the physiological
eHect of smoking or on genetic susceptibility to smoking-related
diseases.
O B J E C T I V E S
The main objective was to determine the eHicacy of providing
smokers with feedback on their exhaled carbon monoxide (CO)
measurement, spirometry results, atherosclerotic plaque imaging,
and genetic susceptibility to smoking-related diseases in helping
them to quit smoking.
The hypotheses to be examined were as follows.
• Feedback on personal characteristics indicating that the
eHects of smoking, or susceptibility to smoking-related illness,
increases rates of smoking cessation.• Multiple types of measurement (e.g. spirometry and exhaled
CO measurement used together) are more eHective for smoking
cessation than a single form of measurement.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials.
Types of participants
We included studies of any individuals who smoked and who
participated in smoking cessation programmes, or in screening
for respiratory disease, or in health checkups. There were no
restrictions on participant age, motivation to quit, or whether
participants were pregnant, were hospitalised, or were suHering
from coexistent illness.
Types of interventions
We included studies of any intervention in which a physical
measurement, such as exhaled carbon monoxide (CO), spirometry,
atherosclerotic plaque imaging, or genetic testing, was used as a
way to increase smoking cessation rate. We considered studies in
which reporting of these measurements was the only component of
an intervention, or was tested as an adjunct to another intervention
such as counselling, where the control group received all other
components except for the reporting of such measurements. We
excluded trials in which the eHect of biological measurements
was confounded by the use of other components in the active
intervention.
Types of outcome measures
The main outcome measure was abstinence from smoking,
measured at least six months aNer the start of the intervention.
We used the most conservative measure of quitting at the
longest follow-up, preferring biochemically validated results where
available. We counted participants lost to follow-up as continuing
smokers. We excluded studies that did not provide data on
cessation but instead measured intermediate outcomes such as
withdrawal symptoms.
Search methods for identification of studies
For this update we searched the Cochrane Tobacco Addiction
Group Specialized Register on 27 March 2018 and the US National
Institutes of Health Ongoing Trials Register ClinicalTrials.gov
(www.clinicaltrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (apps.who.int/
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trialsearch) on 3 September 2018 for studies that involved any
use of a biomedical test as part of an intervention. At the time
of the search, the Register included the results of searches of the
Cochrane Central Register of Controlled trials (CENTRAL), Issue 1,
2018; MEDLINE (via Ovid) to update 20180209; Embase (via Ovid)
to week 201807; and PsycINFO (via Ovid) to update 20180212.
See the Cochrane Tobacco Addiction Group website for full search
strategies and a list of other resources.
We used the following topic-related keywords and text terms to
identify potentially relevant studies:
patient education, patient compliance, patient counselling,
persuasive communication, spirometry, respiratory function,
bronchospirometry, carbon monoxide, forced expiratory flow rates,
obstructive lung diseases, genetic testing, genetic susceptibility,
genetic predisposition, biomarker, feedback.
See Appendix 1 for the full strategy.
Data collection and analysis
Two review authors (out of CC, RB, YM, KS) independently
prescreened all search results (abstracts) for possible inclusion
or as useful background. Studies were selected for full-text
assessment if retained by at least one of the review authors. Two
review authors (out of CC, RB, YM, KS) then independently assessed
the selected articles for inclusion, resolving any discrepancies by
consensus. We have recorded reasons for the non-inclusion of
studies in the Characteristics of excluded studies table.
Each review author then extracted and compared the data from the
selected studies. This stage included an evaluation of risk of bias.
Four review authors independently assessed each study according
to the presence and quality of the randomisation process, whether
or not trialists and assessors were 'blinded', whether the analysis
was appropriate to the study design, and the description of
withdrawals and dropouts. We used Covidence for the screening
and data extraction (Covidence).
We extracted data, where available, on the following.
• Country and setting (e.g. primary care, community, hospital
outpatient/inpatient)• Recruitment• Method of selection of participants (e.g. willingness to make a
quit attempt)• Definition of smoker used• Method of randomisation
• Allocation concealment• Smoking and demographic characteristics of participants (e.g.
average age, sex, average number of cigarettes smoked per day)• Description of the experimental and control interventions
(provider, length, number of visits, etc.)• Outcomes, including definition of abstinence used, and
biochemical validation of cessation• Proportion of participants with follow-up data• Whether or not data were analysed on an intention-to-treat
basis• Appropriateness of statistical approach• Declaration of interest and source of funding
Data synthesis
We expressed results as a risk ratio (RR) for smoking cessation
with 95% confidence intervals (CI). Where appropriate, we pooled
studies using a Mantel-Haenszel random-eHects method. We
assessed heterogeneity using the I2 statistic.
'Summary of findings' table
We created a 'Summary of findings' table for our primary outcome
in accordance with standard Cochrane methodology. We assessed
the certainty of evidence using the five GRADE criteria (study
limitations, consistency of eHect, imprecision, indirectness, and
publication bias).
R E S U L T S
Description of studies
Results of the search
For this update we found 1096 records for screening, from
which we identified five new trials, for a total of 20 trials of
9262 people that met our inclusion criteria. The flow of studies
is reported in a PRISMA flow diagram (Figure 1). We found
15 studies that were potentially eligible and either ongoing
(ACTRN12618000291280; IRCT2017080435257N1; NCT02658032;
NCT02840513; NCT02991781; NCT03521141; NCT03583203), or
finished but with no published data and no information retrievable
through contacting study authors (Martin Lujan 2011; Martin Lujan
2016; NCT01186016; NCT02431611; NCT03377738; Pita Fernandez
2015; Ripoll 2012; Muhammad 2015). Details of these studies can
be found in the Characteristics of ongoing studies table. One study
was ongoing, but there was insuHicient information to assess
its eligibility, therefore we assessed it as awaiting classification
(NCT02351167).
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Figure 1.   (Continued)
 
Included studies
One included study tested two interventions (Audrain 1997). Out
of the 21 interventions, five tested feedback on smoking exposure,
each measuring the eHect of exhaled CO measurements (Audrain
1997; Brunette 2013; Jamrozik 1984; Sanders 1989; Shahab 2011).
Five studies tested feedback on smoking-related disease risk; of
these, four tested feedback about genetic susceptibility to cancer
(Audrain 1997; Hishida 2010; Ito 2006; Nichols 2014), and one tested
feedback about genetic susceptibility to Crohn's disease (Hollands
2012). In Audrain 1997, the intervention was feedback about
genetic susceptibility combined with CO measurement, which
could either be compared to a control group of CO measurement
alone, or to a control group without biomarker feedback, thereby
testing the combination of the two interventions. Eleven studies
assessed feedback on smoking-related harm: four tested the
combination of exhaled CO measurement and spirometry (McClure
2009; Risser 1990; Sippel 1999; Walker 1985); five tested the
eHect of spirometry alone (BuHels 2006; Irizar Aramburu 2013;
Segnan 1991), or with the addition of feedback on lung age
(Drummond 2014; Parkes 2008); two tested the eHect of undergoing
an ultrasonography of carotid arteries (and femoral arteries for
Bovet 2002) with photographic demonstration of atherosclerotic
plaques when present (Bovet 2002; Rodondi 2012).
The trials were conducted in diHerent settings: 11 trials took place
in general practice (BuHels 2006; Irizar Aramburu 2013; Jamrozik
1984; Nichols 2014; Parkes 2008; Sanders 1989; Segnan 1991),
or outpatient clinics (Bovet 2002; Ito 2006; Rodondi 2012; Sippel
1999); one study took place in the community, recruiting first-
degree relatives of probands with Crohn's disease (Hollands 2012);
two took place in smoking cessation clinics (Audrain 1997; Walker
1985); one was conducted in a health promotion clinic for army
veterans (Risser 1990); one was conducted in a mental health
clinic (Brunette 2013); one was conducted in a company (Hishida
2010); and three took place in research institutions (Drummond
2014; McClure 2009; Shahab 2011). Seven trials took place in the
USA (Audrain 1997; Brunette 2013; Drummond 2014; McClure 2009;
Risser 1990; Sippel 1999; Walker 1985), six in the UK (Hollands 2012;
Jamrozik 1984; Nichols 2014; Parkes 2008; Sanders 1989; Shahab
2011), two in Japan (Hishida 2010; Ito 2006), and one trial each took
place in Italy (Segnan 1991), Belgium (BuHels 2006), the Seychelles
Islands (Bovet 2002), Switzerland (Rodondi 2012), and Spain (Irizar
Aramburu 2013).
Methods of recruitment were heterogeneous between studies.
Among the six studies conducted in general practice, one recruited
patients at their first visit (Jamrozik 1984); another screened
outpatients on specific days (Segnan 1991); two screened patients
during the recruitment period (BuHels 2006; Sanders 1989); and
two invited known smokers by post (Parkes 2008; Nichols 2014).
One study recruited smokers among outpatients in primary care
clinics (Sippel 1999); one study recruited outpatients at a cancer
centre hospital (Ito 2006); and one study recruited patients referred
to a mental health treatment clinic (Brunette 2013). Four studies
recruited smokers by media advertisement (Audrain 1997; Rodondi
2012; Shahab 2011; Walker 1985). The remaining studies recruited
smokers participating in a health survey (Bovet 2002); employees
who identified themselves as smokers in a questionnaire used
for an annual workplace checkup (Hishida 2010); veterans that
responded to a mailed invitation to attend a health promotion
clinic (Risser 1990); and participants of a cohort study of people
with a history of injecting drugs (Drummond 2014). Two studies
combined diverse methods of recruitment. One study used media
advertisement, outpatient recruitment, data from health plan
records, a quitline register, and a purchased e-mail list of smokers
(McClure 2009), and another asked probands to identify first-
degree relatives through three routes, first approaching probands
receiving care through hospital services, secondly contacting them
by mail using Crohn's disease databases at 42 participating
hospitals, and finally placing advertisements in the newsletters
of associations (Hollands 2012). One study did not specify the
method of recruitment (data were obtained aNer contacting the
study author; the study is not yet published) (Irizar Aramburu 2013).
Participation rates (i.e. the proportion of those approached who
agreed to take part in the trial) were seldom recorded.
All studies included male and female adults who were smokers
at the time of inclusion. Only 10 studies provided a definition
of being a smoker at the time of inclusion (Audrain 1997; Bovet
2002; Drummond 2014; Hollands 2012; Irizar Aramburu 2013; Ito
2006; McClure 2009; Nichols 2014; Rodondi 2012; Shahab 2011). The
mean age of the participants when given varied between 31.7 and
53.0 years. The proportion of women in the trials varied between
4% and 65%. The mean number of cigarettes smoked per day varied
between 11.9 and 29.2. The mean number of cigarettes smoked per
day tended to be highest in the trials set in a smoking cessation
clinic (29.2 per day in Walker 1985 and 22.7 per day in Audrain
1997) or among veterans (23.5 per day in Risser 1990). Levels
of nicotine addiction as assessed by the Fagerström score were
provided in three studies (Heatherton 1991), and ranged from 3.5 to
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5.4 (Drummond 2014; Nichols 2014; Rodondi 2012); proportions of
participants in the various stages of change according to Prochaska
and Di Clemente were only provided in five studies (Prochaska
1983), with the proportion of participants in the preparation stage
ranging from 17% to 37.5% (Audrain 1997; Ito 2006; McClure 2009;
Parkes 2008; Sippel 1999).
The therapist delivering the intervention was a physician in five
trials (Bovet 2002; BuHels 2006; Irizar Aramburu 2013; Jamrozik
1984; Segnan 1991); a nurse in four trials (Hishida 2010; Risser
1990; Rodondi 2012; Sanders 1989); a specific study staH member in
seven trials (Audrain 1997; Drummond 2014; Ito 2006; Parkes 2008;
Shahab 2011; Sippel 1999; Walker 1985); a trained health educator
or research counsellor in two trials (Hollands 2012; McClure 2009);
the principal investigator with help from trained smoking cessation
practitioners in one study (Nichols 2014); and the intervention and
feedback was web based in one study (Brunette 2013). Further
details on the included studies can be found in the Characteristics
of included studies tables.
Excluded studies
For this update, we excluded 31 studies at full-text screening,
and listed a total of 61 excluded studies. The primary reasons for
exclusion were because the eHect of the biomedical assessment
could not be evaluated separately from the rest of the cessation
intervention; the study had less than six months follow-up; or the
study was not a true randomised trial. The excluded studies along
with reasons for their exclusion can be found in the Characteristics
of excluded studies table.
Risk of bias in included studies
We judged all but three included studies to be at high or unclear risk
of bias in at least one domain (Parkes 2008; Rodondi 2012; Segnan
1991). 'Risk of bias' judgements for each study are displayed in
Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
 
Only six of the 20 included trials reported an adequate procedure
for both randomisation and allocation concealment (Brunette
2013; Drummond 2014; Hollands 2012; Parkes 2008; Rodondi
2012; Segnan 1991). Eight studies did not report the method of
randomisation, or provided insuHicient information to assume that
allocation was adequately concealed (Audrain 1997; Bovet 2002;
BuHels 2006; McClure 2009; Nichols 2014; Risser 1990; Shahab
2011; Walker 1985). Five studies reported inadequate allocation
sequences, with allocation by day, week, or month of attendance
(Hishida 2010; Ito 2006; Jamrozik 1984; Sanders 1989), or by odd-/
even-numbered questionnaire at the time of check-in (Sippel 1999).
In one of these studies, 120 participants were allocated to the wrong
group and were excluded from further analysis (Sanders 1989).
Due to the demonstrative nature of the intervention, participants
and those delivering the intervention could not be blinded to
allocation, therefore we did not assess performance bias, and
assessed detection bias independent of blinding. We judged the
risk of detection bias to be low if abstinence was biochemically
verified, or if the intervention and control groups received
similar amounts of face-to-face contact. If abstinence was not
biochemically verified and the intervention group received more
face-to-face contact than the control group, then we judged the risk
of detection bias to be high because the results may be prone to
diHerential misreport. We judged only one study to be at high risk of
detection bias based on these criteria (Hishida 2010); we assessed
the remaining studies as at low risk of bias.
Three trials used urinary cotinine level to validate smoking
cessation at follow-up (Parkes 2008; Sanders 1989; Segnan 1991).
One study used the same validation procedure but only on
a subsample of self-reported ex-smokers (Jamrozik 1984). Two
studies used expired air carbon monoxide (Risser 1990; Walker
1985). One study used serum cotinine level (Rodondi 2012); one
study used saliva cotinine (Hollands 2012); and two studies used
both exhaled CO and salivary cotinine (Drummond 2014; Nichols
2014). Nine studies did not use any biochemical validation (Audrain
1997; Bovet 2002; Brunette 2013; BuHels 2006; Hishida 2010; Ito
2006; McClure 2009; Shahab 2011; Sippel 1999). Only seven studies
explicitly mentioned that assessors were blinded to allocation at
the time of outcome determination (Bovet 2002; Brunette 2013;
Parkes 2008; Risser 1990; Rodondi 2012; Shahab 2011; Sippel 1999).
In three studies (Audrain 1997; Nichols 2014; Walker 1985), it was
not possible to determine the initial allocation of the participants
who were subsequently lost to follow-up, and the analysis had to
be performed per protocol. This may have overestimated cessation
rates for the individual studies, but impact on meta-analysis results
were probably limited given the limited number of participants in
those three studies. In one study (Hishida 2010), those who were
allocated to the intervention group but who subsequently declined
to participate in biomarker testing were included in the baseline
characteristics table, but were excluded from further analyses.
E4ects of interventions
See: Summary of findings for the main comparison Biomedical
risk assessment compared with standard care or minimal
intervention for smoking cessation
Results are given as risk ratios (RRs) for smoking cessation at
the latest recorded follow-up time (six to 12 months) between
intervention and control groups, with 95% confidence intervals
(CI). An RR greater than one favours the intervention group. We
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classified trials into three analyses by type of intervention: those
that provided feedback on smoking exposure, those that provided
feedback on smoking-related disease risk, and those that provided
feedback on smoking-related harms. Results of the analyses are
reproduced in Figure 3, Figure 4, and Figure 5.
 
Figure 3.   Forest plot of comparison: 1 All interventions, outcome: 1.1 Smoking cessation - feedback on smoking
exposure.
 
 
Figure 4.   Forest plot of comparison: 1 All interventions, outcome: 1.2 Smoking cessation - feedback on smoking-
related disease risk.
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Figure 5.   Forest plot of comparison: 1 All interventions, outcome: 1.3 Smoking cessation - feedback on smoking-
related harm.
 
Feedback on smoking exposure
Five studies isolated the eHect of demonstrating levels of exhaled
CO on smoking cessation rate (Audrain 1997; Brunette 2013;
Jamrozik 1984; Sanders 1989; Shahab 2011). There was no evidence
of a significant benefit from these pooled studies (RR 1.00, 95% CI
0.83 to 1.21; I2 = 0%; n = 2368; Analysis 1.1; Figure 3).
Feedback on smoking-related disease risk
Three trials studied measurements of genetic susceptibility to
smoking-related cancer (Hishida 2010; Ito 2006; Nichols 2014),
and one measured the genetic susceptibility to Crohn's disease
(Hollands 2012). We pooled all five trials and found no evidence of a
significant benefit from these pooled studies (RR 0.80, 95% CI 0.63
to 1.01; I2 = 0%; n = 2064; Analysis 1.2; Figure 4).
We pooled the three trials testing feedback on the genetic
susceptibility to smoking-related cancers and found no evidence
of a significant benefit from these pooled studies (RR 0.84, 95% CI
0.65 to 1.10; I2 = 0%; n = 1297; Analysis 1.2.1). Hollands 2012 did not
detect a benefit from feedback on genetic susceptibility to Crohn's
disease (in relatives of individuals suHering from Crohn's disease)
(RR 0.74, 95% CI 0.32 to 1.71; n = 497).
Feedback on smoking-related harms
Eleven studies provided feedback on smoking-related harm.
Pooling all 11 studies narrowly missed a significant eHect on
smoking cessation (RR 1.26, 95% CI 0.99 to 1.61; I2 = 34%; n = 3314;
Analysis 1.3; Figure 5). However, a sensitivity analysis removing the
three studies at high risk of bias did detect an eHect (RR 1.36, 95%
CI 1.07 to 1.74; I2 = 24%; n = 2710; analysis not shown).
Five studies provided feedback based on spirometry results (BuHels
2006; Drummond 2014; Irizar Aramburu 2013; Parkes 2008; Segnan
1991). There was no evidence of a significant benefit from
spirometry with or without feedback on lung age when the five
studies were pooled (RR 1.24, 95% CI 0.83 to 1.84; I2 = 38%; n =
1728; Analysis 1.3.1). Four trials used exhaled CO measurement
and spirometry together (McClure 2009; Risser 1990; Sippel 1999;
Walker 1985). None of these trials detected a significant eHect
independently, and there was no evidence of a significant benefit
when these studies were pooled (RR 1.27, 95% CI 0.74 to 2.18; I2
= 47%; n = 895; Analysis 1.3.2). Two trials tested ultrasonography
of carotid (and femoral) arteries (Bovet 2002; Rodondi 2012). There
was no evidence of a significant benefit from these pooled studies
(RR 1.56, 95% CI 0.67 to 3.66; I2 = 66%; n = 691; Analysis 1.3.3).
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Multiple versus single forms of measurement
Only one study directly compared multiple forms of measurement
with a single form of measurement (Audrain 1997). The study did
not detect a significant diHerence in eHect between measurement
of CO plus genetic susceptibility to lung cancer and measurement of
CO only (RR 0.82, 95% CI 0.43 to 1.56; n = 189; Analysis 2.1). The other
included studies were too clinically heterogenous to allow indirect
comparisons of multiple versus single forms of measurement.
D I S C U S S I O N
Summary of main results
Due to the scarcity of evidence of suHicient quality, we cannot
make definitive statements about the eHectiveness of biomedical
risk assessment as an aid for smoking cessation. Most studies
were small and did not detect significant eHects. We pooled
studies based on the type of feedback they provided. The most
promising results relate to spirometry and carotid ultrasound,
where moderate-certainty evidence, limited by imprecision and
risk of bias, did not detect a statistically significant benefit, but
confidence intervals very narrowly missed one, and the point
estimate favoured the intervention. A sensitivity analysis removing
those studies at high risk of bias did detect a benefit. Moderate-
certainty evidence limited by risk of bias did not detect an eHect
of feedback on smoking exposure by CO monitoring. Low-certainty
evidence, limited by risk of bias and imprecision, did not detect a
benefit from feedback on smoking-related risk by genetic marker
testing. There is insuHicient evidence with which to evaluate the
hypothesis that multiple types of assessment are more eHective
than single forms of assessment. Results are summarised in
Summary of findings for the main comparison.
Only two studies detected statistically significant intervention
eHects. One of these was a trial in primary care that used spirometry
and immediate feedback of the results using a graphical display
(Parkes 2008). Intervention participants were told their "lung age" if
this was older than their chronological age. The control group also
had spirometry and feedback, but the results were given by letter
in terms of standard measures of lung function, with no mention of
lung age. All participants were advised to quit and oHered a referral
to intensive support. Contact time was longer in the intervention
group because of the verbal feedback. Giving the spirometry results
in terms of lung age resulted in an increase in the cessation rate
at 12 months from 6.4% to 13.6%. In considering the strength of
evidence and generalisability of this trial, it should also be noted
that the outcome was limited to point-prevalence abstinence, and
information was lacking about the comparability of the study
sample with the entire recruitment population. Another study,
retrieved in the current update, also assessed spirometry with lung
age feedback (compared with spirometry results in a standardised
written format) but in a research cohort of intravenous drug users
(Drummond 2014). The sample size was small (50 participants), and
the study did not show a significant benefit of this approach.
The other study with a statistically significant positive eHect
used pictures of ultrasound photographs of atherosclerotic
plaques (Bovet 2002). Participants were randomised to undergo
ultrasonography (n = 74) or not (n = 79). Those with
ultrasonographic demonstration of atherosclerotic plaques (n =
20) were given photographs of their plaques with a relevant
explanation, whereas the others did not benefit from any further
procedure. This study's external validity can be questioned, as the
sample was made up predominantly of male light smokers (average
10 to 12 cigarettes a day). Another study using a similar feedback
method had a larger sample (536 smokers), a larger proportion
of women (45%), and heavier smokers as participants (an average
of 20 cigarettes smoked per day) (Rodondi 2012). This study did
not show a statistically significant eHect of the intervention. The
authors noted in their discussion that they included only smokers
with a motivation to quit and that they used a very intensive
smoking cessation programme in both the intervention and control
groups.
While the evidence does not directly support the use of biomedical
risk assessment for smoking cessation, more research is needed
before we can be confident in this result.
Overall completeness and applicability of evidence, and
limitations of the review
Cochrane methods are designed to minimise bias in the review
process. However, due to the nature of the intervention, there
were some diHiculties in finding suitable evidence. In most of the
included studies, the biomedical testing component was added
to intensive quit-smoking sessions, with counselling lasting up to
60 minutes and completed by written material and reinforcement
sessions or follow-up phone calls. The incremental eHect of
biomedical risk assessment might have been diluted by the high
intensity of the 'standard' care used. It is also possible that
the changes in motivational stages induced by biomedical risk
assessment are too subtle to be characterised as directly leading
to a successful quit attempt. Data from those studies do not permit
verification of this hypothesis. However, given the increasing
evidence that the transtheoretical model of behaviour change is not
a mandatory prerequisite for a smoking cessation intervention to
be eHective (Cahill 2010; Riemsma 2003), we do not consider this
lack of intermediate data to be a major concern.
Biomedical risk assessment was also conceptualised as a part
of multicomponent interventions (with components other than
biomedical risk assessment) by some authors of studies identified
by our search strategy (Borrelli 2002; Borrelli 2005; Ferketich 2012;
Hajek 2002; Humerfelt 1998; Kotz 2009; Martucci 2010; McBride
2002; McClure 2013; Prokhorov 2008; Richmond 1986). Even though
four of these studies demonstrated eHects significantly favouring
intervention versus control groups, they did not isolate the specific
eHect of biomedical feedback. The retrieved studies also did
not provide us with suHicient data to adequately examine our
second research hypothesis, that feedback with diHerent types
of measurements is more eHective for smoking cessation than
feedback of a single measurement.
Another possible explanation for the absence of eHectiveness
of biomedical risk assessment provided in addition to
counselling could be the potentially counterproductive eHect
of communicating normal results to smokers. Six included
studies provided some insight about smoking cessation rates in
subgroups according to test results. Sippel 1999, BuHels 2006,
and Parkes 2008 did not find any correlation between smoking
cessation and abnormal spirometry results. Bovet 2002, which
overall detected significantly higher cessation rates in participants
oHered ultrasonography, found a statistically non-significant lower
smoking cessation rate among the subgroup of participants
without plaques at ultrasonography than among participants in the
Biomedical risk assessment as an aid for smoking cessation (Review)
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control group. Rodondi 2012 found that, in the ultrasonography
group, cessation rates did not diHer according to the presence
or absence of atherosclerotic plaques. Parkes 2008 noted that
anecdotally some smokers were motivated by having normal
results because it helped them feel it was "not too late" to quit. Ito
2006 found some evidence that among participants without cancer,
those told they had increased susceptibility to cancer were more
likely to quit. This particular question, and the way to handle and
communicate normal results, has yet to be answered.
Trials demonstrating smoking-related harms using spirometry
(especially when combined with lung age) or carotid ultrasound
tended to show a stronger eHect on smoking cessation, though
this eHect was not significant. This could be explained by the fact
that direct and concrete demonstration of manifest harm might
be more likely to motivate smokers to quit smoking, according to
the Leventhal Common Sense Model (Hale 2007). It might be more
straightforward for a smoker to establish a causal link between
smoking and a direct and "noticeable" harm such as lung damage
(increased lung age) or carotid plaques. Inversely, feedback on
smoking exposure, using indirect and more obtuse measures such
as CO, might not be suHicient to motivate a change in behaviour.
Genetic feedback might be even more diHicult to understand and
counterproductive in the sense that people might believe that risks
are not modifiable due to the deterministic aspect of genetics.
Two other trials used demonstration of smokers' children's
exposure to environmental tobacco smoke by measuring the child's
urinary cotinine level (abstinence was a secondary outcome) and
demonstration of Latino caregivers' asthmatic children's exposure
to secondhand CO (Borrelli 2010; Wakefield 2002), with RRs of 0.26
(95% CI 0.02 to 2.33) and 0.90 (95% CI 0.72 to 1.12), respectively.
A third study evaluated the eHicacy of personalised feedback
during foetus ultrasound on pregnant smokers (Stotts 2009), and
again did not detect a benefit (RR 1.31, 95% CI 0.66 to 2.58). We
excluded these studies from our analysis because our research
hypothesis was that smokers, although adept at estimating the
risks of smoking in terms of morbidity and mortality, are prone
to underestimate their own risk with regard to smoking (Lerman
1993; Romer 2001). It therefore seemed to us that providing
biomarker feedback about someone else's health (even one's own
children or foetus) would act diHerently and may not contribute
to counteracting this personal optimistic bias. In any event, these
trials did not detect benefits for the interventions tested.
A promising new approach could be for dental practitioners to use
a point-of-care test for salivary nicotine metabolites. A short-term
randomised controlled trial compared smoking cessation aNer
eight weeks among participants who received either counselling
with immediate or delayed (at the end of the study) feedback on
salivary nicotine level (Barnfather 2005). The risk ratio for smoking
cessation is close to being statistically significantly in favour of
those who received immediate feedback: RR of 3.40 (95% CI 1.00 to
11.61). Trials with longer-term follow-up are needed to confirm this
eHect (Coleman 2005).
Despite broad inclusion criteria regarding the type of participants,
we found only scarce data exploring the eHect of biomedical risk
assessment on hospitalised patients or acutely ill individuals. It is
possible that such a specific context and the presence of coexistent
illnesses could facilitate a modification of risk perception. One
study included participants both with and without cancer (Ito
2006). Reported subgroup analyses did not detect benefits either
for participants with cancer (RR 0.65, 95% CI 0.43 to 1.02) or for
participants without cancer (RR 1.22, 95% CI 0.63 to 2.36).
Some recent studies used connected devices such as mobile-
phone applications (ACTRN12618000291280; NCT02840513;
NCT03583203), or provided web-based feedback (Brunette 2013).
Biofeedback on lung damage or risk of lung cancer, or both, is a
well-represented intervention in ongoing studies (NCT02658032;
NCT03521141; NCT03583203).
Certainty of the evidence
The certainty of the evidence using GRADE criteria was low to
moderate, depending on feedback category. The evidence on
interventions providing feedback on risk exposure was of moderate
certainty, limited by risk of bias because three of the five studies
were at high risk of bias, and the remaining studies were at unclear
risk of bias. The evidence on interventions providing feedback
on smoking-related disease risk was of low certainty, limited by
risk of bias and imprecision because fewer than 300 events were
recorded. The evidence on interventions providing feedback on
smoking-related harm through spirometry or carotid ultrasound
was of moderate certainty, limited by imprecision and risk of
bias because the confidence intervals only narrowly missed a
statistically significant benefit, and a sensitivity analysis excluding
studies at high risk of bias did detect one.
Agreements and disagreements with other studies or
reviews
An earlier non-systematic review was conducted on the use
of biomarkers in smoking cessation (McClure 2001). This work
aimed to review the theoretical rationale and empirical evidence
regarding this practice, and therefore did not specifically focus
on the assessment of the eHicacy of biomarker feedback as a
way to increase rates of long-term smoking cessation. The review
therefore included non-randomised trials (Haddow 1991; Kilburn
1990; Loss 1979; Scott 1990); trials providing multicomponent
interventions that precluded the isolation of the specific eHect
of biomarker feedback (Bauman 1983; Lerman 1997; Richmond
1986); trials comparing the eHect of abnormal test results versus
normal test results rather than test versus no test (Li 1984); and
trials reporting outcomes other than smoking cessation. One study
identified by McClure as "in press" appears never to have been
published (HoHman 1998), and we were unable to obtain further
information despite several attempts to contact the authors. Four
studies mentioned by McClure were also included in our review
(Audrain 1997; Jamrozik 1984; Risser 1990; Walker 1985). Our review
includes 16 trials not in the McClure review (Bovet 2002; Brunette
2013; BuHels 2006; Drummond 2014; Hishida 2010; Hollands
2012; Irizar Aramburu 2013; Ito 2006; McClure 2009; Nichols 2014;
Parkes 2008; Rodondi 2012; Sanders 1989; Segnan 1991; Shahab
2011; Sippel 1999). When focusing on eHicacy data, McClure 2001
concluded that biomarker feedback may enhance the likelihood
of cessation because a trend for increased abstinence was found
in three randomised trials (HoHman 1998; Risser 1990; Walker
1985). The fact that two of these trials, Walker 1985; Risser 1990,
are subject to major methodological limitations (small samples,
inadequate randomisation procedures), and that the report of
HoHman 1998 remains unpublished, calls for great caution in
drawing such conclusions.
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A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found little evidence about the eHects of biomedical risk
assessment as an aid for smoking cessation. However, the
current evidence base does not support the use of biomedical
risk assessment as an aid for smoking cessation. The most
promising results relate to spirometry and carotid ultrasound,
where moderate-certainty evidence, limited by imprecision and
risk of bias, did not detect a statistically significant benefit, but
confidence intervals very narrowly missed one, and the point
estimate favoured the intervention. A sensitivity analysis removing
those studies at high risk of bias did detect a benefit. Moderate-
certainty evidence limited by risk of bias did not detect an eHect
of feedback on smoking exposure by carbon monoxide monitoring.
Low-certainty evidence, limited by risk of bias and imprecision,
did not detect a benefit from feedback on smoking-related risk by
genetic marker testing. There is insuHicient evidence with which to
evaluate the hypothesis that multiple types of assessment are more
eHective than single forms of assessment.
Implications for research
There is room for improvement in the methodological quality
of studies aimed at evaluating the eHicacy of biomedical risk
assessment as an aid to smoking cessation. In particular, further
studies assessing feedback on smoking-related harm could be
more beneficial than those assessing feedback on smoking
exposure or smoking-related disease risk. Future studies should
aim to have adequate sample sizes; conceal allocation following
the randomisation procedure; use a standard definition of a smoker
and of abstinence from smoking; systematically use biochemical
validation of smoking abstinence; and include of all those lost to
follow-up in the denominator of each group (on an intention-to-
treat basis).
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Characteristics of included studies [ordered by study ID]
 
Methods Setting: "smoking clinic", USA
Recruitment: press
Selected: advertisement: "free smoking-cessation study"
Participants 550 smokers (defined as >= 5 cpd for >= 1 year) out of 1104 eligible; mean age 44 years, 62.8% female,
83.9% white, mean cpd: 22.7
Stage of change: Preparation stage: 37.5%, mean Fagerström score: 5.4
Therapist: trained health educator
Interventions Control: QSC group: 60-minute Quit-Smoking Consultation (QSC) (quit plan, gaining support).
Intervention 1: Exposure Biomarker (CO) Feedback (EBF) plus 10-minute motivational counselling be-
fore QSC.
Intervention 2: Susceptibility Biomarker (CYP2D6) Feedback plus 10-minute motivational intervention
plus EBF plus QSC
Outcomes Definition of abstinence: 30-day abstinence
Duration of follow-up: 12 months
Audrain 1997 
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Biochemical validation of non-smokers: none
Identification  
Notes Source of funding: Grant ROI CA63562 from the National Institutes of Health, National Cancer Institute.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised between 2 interventions and control, method not described
Allocation concealment
(selection bias)
Unclear risk No details given.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence not biochemically validated, but similar amounts of face-to-face
contact between groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Per-protocol analysis, 33% lost to follow-up. Distribution of baseline 550 par-
ticipants among the 3 groups not reported. "There were no significant differ-
ences between treatment groups with respect to loss to follow-up."
Audrain 1997  (Continued)
 
 
Methods Setting: Seychelles Heart Study II
Recruitment: age- and sex-stratified sample drawn from general population of Mahé, invited by letter
to a cardiovascular risk factor survey
Selected: last 155 participants to the Seychelles Heart Study II who reported smoking.
Participants 155 smokers (defined as >= 1 cpd during previous week); mean age 46 years, 15% female, mean cpd:
11.9
Therapist: physician
Interventions Intervention: ultrasonography of carotid and femoral arteries + quit-smoking counselling. Smokers
with >= 1 plaque given 2 photographs of their plaque plus explanation.
Control: quit-smoking counselling
Outcomes Definition of abstinence: 7-day abstinence
Duration of follow-up: 6 months
Biochemical validation of non-smokers: none (assessor blinded)
Identification  
Notes Source of funding: This study was supported by the Ministry of Health of Seychelles, the University In-
stitute of Social and Preventive Medicine of Lausanne (Switzerland), and the Division of Cardiology of
the University Hospital of Lausanne.
P Bovet benefited from a grant from the Swiss National Science Foundation (No. 3233-038792.93). F
Paccaud benefited from a grant from the Swiss National Science Foundation (No. 3233-038792.93). F
Paccaud benefited from grants from the "Fondation Vaudoise de Cardiologie" and the "Fondation Em-
ma Muschamp" (Switzerland).
Sonotron Ltd (Switzer-products) provided the echographic system for the study, and Air Seychelles
transported this equipment free of charge.
Bovet 2002 
Biomedical risk assessment as an aid for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
26
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Pre-established random sequences of numbers matched to rank of arrival
Allocation concealment
(selection bias)
Unclear risk Unclear whether allocation was concealed or not
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No biochemical validation, but follow-up assessors blinded to allocation group
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 participants lost to follow-up, not included for analysis
Bovet 2002  (Continued)
 
 
Methods Setting: large mental health treatment organisation, Chicago, USA
Study design: randomised controlled trial
Study grouping: parallel group
Screened participants: 279 referred participants
Included participants: 124
Intention-to-treat analyses: not specified
Participants Inclusion criteria: adult, English-speaking, daily smoker, in treatment for severe mental illness (de-
fined as mood or psychotic disorder with persisting functional disability) at the mental health program
Exclusion criteria: current other substance dependence; used smoking cessation treatment to try to
quit in the past month
Baseline characteristics: mean age 46.5 years, 28.2% female, 48.4% African-American, 15.0 mean
number of cigarettes per day
Interventions Intervention characteristics
Intervention: Decision support system (DSS) with CO
• Description of intervention: multicomponent web-based DSS with CO feedback• How was the intervention performed: information about CO, reading of the level, and brief interpreta-
tion of the reading
Control: DSS without CO
• Description of intervention: multicomponent web-based DSS without CO feedback
Outcomes Smoking cessation: 7-day point-prevalence abstinence at 2 and 6 months, self-reported
Identification Country: USA
Setting: Thresholds, a large mental health treatment organisation in Chicago
Brunette 2013 
Biomedical risk assessment as an aid for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
27
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Author's name: Mary F Brunette, MD
Institution: Geisel School of Medicine at Dartmouth and Dartmouth Psychiatric Research Center, Con-
cord, NH 03301, USA
Email: Mary.F.Brunette@Dartmouth.Edu
Address: Geisel School of Medicine at Dartmouth College, 46 Centerra Parkway, EverGreen Center,
Suite 315, Lebanon, NH 03766, USA
Notes 6-month outcome data by arm obtained directly from main author.
Source of funding: This research is funded in part by the US Department of Education, National Insti-
tute on Disability and Rehabilitation Research and the Substance Abuse and Mental Health Services
Administration, Center for Mental Health Services and Consumer Affairs Program, under Cooperative
Agreement No. H133B100028.
This research was also supported by the Bristol-Myers Squibb Foundation.
The views expressed in this manuscript do not reflect the policy or position of any federal agency.
Declaration of interest: The authors do not have any competing interests to report.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-based randomisation program (using blocks of 10) assigned partici-
pants to use the multicomponent decision support system with or without the
CO feedback.
Allocation concealment
(selection bias)
Low risk Computer based. Research assistant adherence to the decision support sys-
tem study visit protocol was assessed with a 10-item checklist. Adherence to
the visit protocol was high (mean score 9.6 out of 10) and did not differ be-
tween treatment groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence not biochemically validated, but similar amounts of face-to-face
contact between groups.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 3 participants did not complete the 2-month assessment. Numbers not com-
pleting 6-month assessment not given.
Other bias Low risk 6-month outcome not reported by allocation arm, but information was re-
trieved directly after contacting the authors.
Brunette 2013  (Continued)
 
 
Methods Setting: 14 general practices, Belgium
Recruitment: screening of all attending patients above 15 years of age
Selected: smokers in the motivation or action stage
Participants 215 randomised out of 1206 screened smokers. 182 analysed. Smoker definition not given. Mean age:
47.0, 47.3% female, mean pack-years: 24.6
Therapist: physicians
Interventions Intervention: spirometry plus control intervention
Bu4els 2006 
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Control: minimal intervention based on the 5A model: ask, advise, assess, assist, arrange plus quit date
plus NRT or bupropion plus follow-up contact
Outcomes Definition of abstinence: continuous abstinence from quit date
Duration of follow-up: 12 months (24-month data not used in analysis because of increasing loss to
follow-up)
Biochemical validation of non-smokers: none at the 12-month follow-up. Very partial at 24 months
Identification  
Notes Additional data provided by author.
Source of funding: This study was realised with an unconditional grant by Voorzorgskas voor Geneesh-
eren, Brussels, Belgium.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by coin toss
Allocation concealment
(selection bias)
Unclear risk No statement that random sequence generated by coin toss was concealed at
time of enrolment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation of abstinence requested, but few completed. Similar
amounts of face-to-face contact between groups
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 13 (13%) intervention, 20 (18%) control lost before 6 months, all losses includ-
ed as smokers.
Bu4els 2006  (Continued)
 
 
Methods Setting: AIDS Linked to the Intravenous Experience (ALIVE) study, a prospective, longitudinal cohort of
people with a history of injecting drugs, Baltimore, USA
Study design: randomised controlled trial
Study grouping: parallel group
Comment: factorial design
Duration of inclusion: from 16 March 2011 to 3 February 2012 = 1 year
How sample size is determined: not specified
Duration of follow-up: 6 months
Intention-to-treat analyses: yes
Number of participants screened for eligibility: 265
Number of participants included: 100
Participants Inclusion criteria: injection drug users (current and former) from ALIVE cohort; smoking at least 100
cigarettes in their lifetime as well as reporting any cigarette smoking in the last month; interested in in-
volvement in a smoking cessation trial; ability to perform spirometry
Drummond 2014 
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Exclusion criteria: current involvement in a smoking cessation programme; current use of nicotine re-
placement therapy or other smoking cessation pharmacological treatments (bupropion, varenicline)
Definition of smokers: history of smoking at least 100 cigarettes in their lifetime and reporting any cig-
arette smoking in the last month
Study population: residents of Baltimore with a history of injecting drugs
Baseline characteristics (range of medians or proportions across arms)
• Mean age: 46.1 (8.9) to 51.2 (7.5)• % women: 42% to 65%• % African-American: 75% to 100%• %IDU: 12% to 33%• Pack-years, median: 17.8 to 20.3• Fagerström score, median: 3.5 to 4• Age at smoking initiation, mean: 14.9 to 17.1• Predicted FEV1, %: 84.1 to 93.7• FEV1/FVC, %: 0.72 to 0.76
Interventions Intervention characteristics
Experimental intervention A: lung age
• Detailed description of the intervention: spirometric results reviewed in the context of lung age vs
chronological age
Experimental intervention B: contingency management
• Detailed description of the intervention: USD 25 to 50 for each eCO < 7 ppm
Experimental intervention C: lung age plus contingency management
• Detailed description of the intervention: lung age and contingency management
Control intervention: usual care
• Detailed description of the intervention: review of baseline spirometry results of their lung function
reported as a % of predicted values communicated in a standardised written format
Outcomes Smoking cessation: 7-day point-prevalence abstinence, validated
• Notes: 7-day point-prevalence abstinence at 6 months, validated with exhaled CO 7 ppm and salivary
cotinine 6 ng/mL
Smoking cessation: 7-day point-prevalence abstinence self-reported
Identification Country: USA
Setting: AIDS Linked to the Intravenous Experience (ALIVE) study, a prospective, longitudinal cohort of
people with a history of injecting drugs followed in Baltimore, Maryland since 1988
Author's name: Michael B Drummond
Institution: Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD,
USA
Email: mdrummo3@jhmi.edu
Address: Johns Hopkins University, Baltimore, MD, USA
Notes Source of funding: This study was funded primarily by a Tobacco Dependence Research Fund from the
American Thoracic Society (Principal Investigator: Drummond). This work was also supported in part
Drummond 2014  (Continued)
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by the National Institutes of Health (grants R01-HL-90483, R01-DA-04334, and R01-DA-12568). The fund-
ing sources had no role in study design, collection, analysis, or interpretation of data, writing the manu-
script, or decision to submit for publication.
Declaration of interest: All authors have no financial conflict of interest to disclose.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation sequence was computer generated using a block randomisa-
tion approach with randomly ordered 4 and 8 sample blocks.
Allocation concealment
(selection bias)
Low risk 120 sequentially numbered, opaque, sealed envelopes that included random
assignment to 1 of 4 interventions were externally prepared. Study staH were
provided the next sequential envelope which assigned the intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not clear
Drummond 2014  (Continued)
 
 
Methods Setting: a bank in Japan
Recruitment/selection: employees who indicated they were smokers on a questionnaire used at an
annual workplace health checkup
Participants All 562 eligible participants were included. No inclusion or exclusion criteria apart from being an em-
ployee of the bank and identifying as a smoker in the questionnaire.
Smoker definition not given. 6.2% female. Stage of quitting smoking at initiation: "no concern" 20.3%
in intervention group vs 17.0% in control group; "no intention" 73.4% vs 79.3%; "wish to quit" 5.9% vs
3.3%; "no answer" 0.3% vs 0.4%
Therapist: public nurses
Interventions All participants received a booklet on tobacco-related diseases, concept of tobacco carcinogen suscep-
tible genotypes, and benefits of smoking cessation.
Intervention group: participants who agreed to genotype testing had a blood sample taken. The staH
handed a report of the results with a written explanation to each of the participants at 3 months. In the
reports, an explanation was attached that smoking elevates the risk of oesophageal cancer substantial-
ly among those with genotypes SS (OR = 8) and LS (OR = 7), while OR = 2 among those with LL genotype,
and similar for lung cancer. The staH added general comments on the genotype for each participant,
and provided specific comments when participants asked for details. 29 participants allocated to geno-
typing group refused genotype testing. They were later excluded from analysis.
Control group: no further intervention
Outcomes Abstinence assessed by postal questionnaire (no validation).
Duration of follow-up: 12 months
Hishida 2010 
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No definition of abstinence provided.
Identification  
Notes New for 2012 update
Source of funding: This study was supported in part by a Grant-in-Aid for Cancer Research from the
Japanese Ministry of Health, Labour and Welfare.
Declaration of interest: The authors have no conflicts of interest to declare.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Pseudo-random allocation by month of attendance
Allocation concealment
(selection bias)
High risk Allocation known at time of enrolment may lead to selection bias.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Abstinence not biochemically validated, and difference in face-to-face contact
between intervention arms.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Lost to follow-up (no response to follow-up questionnaire) 16.1% in interven-
tion group, 11.2% in control group.
Other bias Unclear risk A law against smoking in the workplace was issued in August 2002 in Japan,
which may be a confounding factor.
Hishida 2010  (Continued)
 
 
Methods Setting: family clusters of relatives of people with Crohn's disease
Study design: cluster-randomised controlled trial
Study grouping: parallel group
Duration of follow-up: 6 months
Duration of inclusion: April 2007 to September 2010
How sample size is determined: the sample size was originally set at 540 participants (270 per arm)
with an anticipated follow-up of 430 participants (projected 80% follow-up rate). We allowed for clus-
tering of participants in families by assuming an intracluster correlation no greater than 0.6 and a mean
cluster size of 1.13 derived from a pilot study.
Intention-to-treat analyses: yes
Type of recruitment:
• Approaching probands receiving care through hospital services• Obtaining addresses of probands through Crohn's disease databases at 42 participating hospitals• Advertising in the newsletters of the National Association for Colitis and Crohn's Disease and the char-
ity Ostomy Lifestyle
Consecutive recruitment: no
Hollands 2012 
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Number of participants screened for eligibility: 1890
Number of participants included: 497
Participants Inclusion criteria:
• First-degree relatives of probands with Crohn's disease• > 18 years old smokers• Smoked 5 or more cigarettes daily
Exclusion criteria: having a diagnosis of Crohn's disease or ulcerative colitis
Definition of smokers: smoking 5 or more cigarettes daily
Baseline characteristics
Intervention:
• Mean age: 42 (14.0)• % women: 145 (58)• % white: 240 (96)• %least deprived: 133 (53)• Number of participants: 251
Control
• Mean age: 43 (14.8)• % women: 150 (61)• % white: 241 (98)• % least deprived: 137 (56)• Number of participants: 246
Interventions Intervention characteristics
Intervention: DNA arm
• Detailed intervention: communication of risk assessment for Crohn's disease by postal booklet based
on family history of the disease, smoking status, and additional DNA analysis for the NOD2 genotype
--> followed by telephone by an NHS stop smoking counsellor to review the booklet and deliver brief
standard smoking cessation intervention
Control: non-DNA arm
• Detailed intervention: communication of risk assessment for Crohn's disease by postal booklet based
on family history of the disease and smoking status alone --> followed by telephone by an NHS stop
smoking counsellor to review the booklet and deliver brief standard smoking cessation intervention
Outcomes Smoking cessation: 7-day point-prevalence abstinence validated
• Notes: reporting smoking no more than 5 cigarettes in the previous 7 days, validated by saliva cotinine
(< 15 ng/mL)
Smoking cessation: 7-day point-prevalence abstinence self-reported
Identification Country: UK
Setting: First-degree relatives of probands with Crohn's disease
Comments: NA
Author's name: Theresa M Marteau
Hollands 2012  (Continued)
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Institution: Department of Psychology (at Guy's), Section of Health Psychology
Email: theresa.marteau@kcl.ac.uk
Address: King's College London, London SE1 9RT, UK
Notes Source of funding: This study was funded as part of a grant from the Medical Research Council,
UK (Risk communication in preventive medicine: optimising the impact of DNA risk information;
G0500274). NJP and CGM are supported by the National Institute for Health Research (NIHR) Biomed-
ical Research Centre at St Guy's and St Thomas' NHS Foundation Trust in partnership with King's Col-
lege London. AF is supported by NIHR through the Comprehensive Biomedical Research Centre at
UCLH/UCL. The trial protocol was peer reviewed by the Council. Other than as indicated, the funder
had no role in the design and conduct of the study; collection, management, analysis, and interpreta-
tion of the data; and preparation, review, or approval of the manuscript.
Declaration of interest: All authors have completed the ICMJE uniform disclosure form at www.icm-
je.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support
from any organisation for the submitted work; no financial relationships with any organisations that
might have an interest in the submitted work in the previous 3 years; and no other relationships or ac-
tivities that could appear to have influenced the submitted work.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The trial statistician prepared the randomisation sequence using randomly se-
lected block sizes of 6, 8, and 10 with randomly permuted allocations within
each block, and with an equal allocation ratio. Participants were randomised
by family cluster. Each participant was allocated by using the next assignment
in the sequence, with clusters of participants required to be allocated to the
same arm along the sequence.
Allocation concealment
(selection bias)
Low risk The randomisation sequence was concealed from the trial co-ordination team
and research counsellor, and the statistical team was only given study data
needed for randomisation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Completed primary outcome measure: 209/251 (83%) for the DNA risk assess-
ment group and 217/246 (88%) for the non-DNA risk assessment group
Other bias Unclear risk Table 3 reports a total number of participants in the DNA arm of n = 232,
whereas only n = 226 received the intervention according to Figure 2.
Hollands 2012  (Continued)
 
 
Methods Study design: randomised controlled trial
Study grouping: parallel group
Comment: sample size not reached; clustering by practice not taken into account in analysis.
Duration of follow-up: 1 year
Duration of inclusion: not specified
Irizar Aramburu 2013 
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How sample size is determined: based on assuming a level of significance of 5%, a quit rate after brief
antismoking intervention only (control group) of 5%, an expected quit rate in the experimental group
of 14%, and a 1:1 ratio of control to experimental participants. Given these premises, to obtain a power
of 80% to detect differences in the test of the null hypothesis Ho: p1 = p2 using a 2-tailed Chi2 test for 2
independent samples, it would be necessary to include 166 experimental units in the reference group
and a further 166 in the experimental group, making a total of 332 units for the study. Assuming a loss
to follow-up of 25%, it would be necessary to recruit 222 participants for the reference group and a fur-
ther 222 for the experimental group, summing to the aforementioned total of 444 participants for the
study.
Intention-to-treat analyses: yes
Number of participants included: 335
Number of participants screened for eligibility: 1775
Participants Baseline characteristics
Overall
• Mean age: 53.6 (SD 8.1)• % women: 51.6%• Number of participants: 335
Inclusion criteria: active smokers; older than 40 years of age; more than 10 pack-year history of smok-
ing; have not been diagnosed with COPD
Exclusion criteria: older than 80 years of age or institutionalised or having a life expectancy of less
than 1 year; having undergone spirometry testing within the previous 2 years; previously diagnosed
with respiratory diseases (asthma, interstitial lung diseases, or COPD) that cause pattern changes in
spirometry tests; having contraindications for spirometry testing
Pretreatment: no full text available
Definition of smokers: > 10 pack-years
Study population: primary care active smokers > 40 years without COPD
Interventions Intervention characteristics
Experimental intervention
• Detailed intervention: the intervention consists of the nurse collecting data, performing a spirometry
test, and then giving the participant an appointment with their general practitioner (GP) within 10
days. At this appointment, the doctor will deliver a brief antismoking intervention and provide the
participant with a short explanation of the spirometry results. Both the delivery of the advice and the
spirometry report will be carried out in a standardised way (in accordance with the guidelines) -->
follow-up: contact by telephone 1 and 3 months after the intervention to determine whether they have
stopped smoking and, if they have not, how many cigarettes they are smoking per day at the time.
Control intervention
• Detailed intervention: the nurse will only interview the participant to collect data on the study vari-
ables and make them an appointment with their GP within 10 days. The doctor will just perform the
brief antismoking intervention in the same standardised way as for the intervention group. These par-
ticipants will not undergo spirometry during the study period of 1 year --> follow-up: contact by tele-
phone 1 and 3 months after the intervention to determine whether they have stopped smoking and,
if they have not, how many cigarettes they are smoking per day at the time.
Outcomes Smoking cessation: 7-day point-prevalence abstinence validated by exhaled CO < 10 ppm
Identification Sponsorship source: International Centre of Research Excellence in Chronicity, Kronikgune, and the
Department of Health of the Basque Government
Irizar Aramburu 2013  (Continued)
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Country: Spain
Setting: primary care (general practitioners from health centres)
Comments: 39 health professionals work in 22 health centres
Author's name: María Isabel Irizar-Aramburu
Institution: Idiazabal Primary Care Medical Centre, Idiazabal, Gipuzkoa, Spain
Email: MARIAISABEL.IRIZARARAMBURU@osakidetza.net
Address: Idiazabal Primary Care Medical Centre, Idiazabal, Gipuzkoa, Spain
Notes Results provided by authors upon request.
Source of funding: We would also like to thank the International Centre of Research Excellence in
Chronicity, Kronikgune and the Department of Health of the Basque Government's decision to fund this
project.
Declaration of interest: The authors declare that they have no competing interests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Doctors will send data on the patients recruited to the Primary Care
Research Unit of the Gipuzkoa Health Region where the patients will be ran-
domly assigned to the intervention or control group. The randomization se-
quence will be generated by computer and kept in the research unit. The list of
patients assigned to each group will be sent to the nurses in charge of the first
appointment. At this appointment, once written informed consent has been
given, the interventions detailed below will be performed for each group."
Allocation concealment
(selection bias)
High risk Nurse in charge of organising appointment aware of allocation before confirm-
ing consent. Imbalance between size of groups (159 vs 176).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated. Assessment of outcome made by health
professionals blinded to the group allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 7 lost to follow-up out of 335 individuals.
Irizar Aramburu 2013  (Continued)
 
 
Methods Setting: first visit at Aichi Cancer Center Hospital (ACCH), Japan
Recruitment: screening of first-visit outpatients (whether consecutive or not is unknown)
Participants 697 included out of 859 eligible smokers. Smoker defined as smoking at least 1 cigarette on the previ-
ous day. Mean age 46.5, 40.5% female, mean cpd: 22.2, pre-contemplator/contemplator: 70%
Therapist: trained interviewer
Interventions Intervention: information at baseline on the effect of L-myc polymorphism on modulating the risk of
cancer due to smoking (5 to 10 minutes). Sent genotype report at 3 months, with same information
about effect of polymorphism (65% got genotype information)
Control: just followed-up for smoking status
Ito 2006 
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Outcomes Definition of abstinence: point prevalence at 9 months (continuous abstinence, not smoking at both
the 3- and 9-month follow-ups also reported, but genotype only provided after 3 months follow-up)
Duration of follow-up: 9 months
Biochemical validation of non-smokers: none (attempt made but none agreed to return for CO mea-
surement)
Identification  
Notes Not given genotype until 3 months. Most participants in both groups had already quit at 3 months,
small proportion of new quitters after 3 months.
Source of funding: This work was supported in part by a Grant-in-Aid for Cancer Research from the
Japanese Ministry of Health, Labor and Welfare (17-1).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Pseudo-random allocation by week of attendance
Allocation concealment
(selection bias)
High risk Allocation known at time of enrolment, so potential for selection bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes assessed by postal questionnaire, biochemical validation attempt-
ed but refused. Similar amount of contact between groups
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Complete data for 52.9% (369), did not differ significantly between groups
Ito 2006  (Continued)
 
 
Methods Setting: 6 general practices, the UK
Recruitment: clinic, first visit
Selected: outpatients
Participants 2110 smokers (defined as a person admitting to smoking cigarettes) out of 6052 screened. 1040 in rele-
vant arms
61% female, no detailed patient characteristics given. Significant difference of social classes between
groups
Therapist: physician
Interventions Intervention: demonstration of participant exhaled CO plus verbal advice plus booklet
Control: verbal advice plus booklet
2 study arms were not relevant to this review
Outcomes Definition of abstinence: point prevalence
Duration of follow-up: 12 months
Biochemical validation of non-smokers: urinary cotinine in a sample (41%) of self-reported non-
smokers
Identification  
Jamrozik 1984 
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Notes Outcome based on unvalidated data. Between 24% and 40% may have misrepresented smoking status,
but no evidence of differential misreporting between groups.
Sources of funding: NuHield Dominions Trust and the Health Education Council. National Institute
on Drug Abuse, DA 2507, D A0007 for cotinine assays. Helen Van Vunakis is the recipient of a US Public
Health Service Career Award 5K6/A 12372.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Randomised according to day of attendance, balanced over 4 weeks
Allocation concealment
(selection bias)
High risk Allocation known at enrolment, possibility of selection bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome based on unvalidated data. Between 24% and 40% may have mis-
represented smoking status, but no evidence of differential misreporting be-
tween groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 28% lost to follow-up across all 4 arms, treated as smokers. No information on
differential loss
Jamrozik 1984  (Continued)
 
 
Methods Setting: Group Health Center for Health Studies, Seattle, Washington, USA (research institution)
Recruitment: health plan records, data from the Washington State Quitline, purchased mailing list of
smokers, ads in local media, public clinics, and other local venues
Participants 536 smokers (with elevated expired CO levels >= 10 ppm and a mean of 15 cpd for the past year or
smoked >= 10 cpd but had smoked for >= 10 years), mean age 50.8 years, 53.2% female, 24.8% pre-con-
templation, 50.8% contemplation, 24.2% preparation, mean cpd: 20.7
Therapists: health educators
Interventions Intervention: brief (20 minutes), personally tailored counselling sessions based on lung functioning
(spirometry), CO exposure, and smoking-related health conditions
Control: generic smoking risk information and personalised counselling about diet, body mass index,
and physical activity
All were advised to quit smoking and were offered access to a free phone-counselling programme.
Outcomes Definition of abstinence: 7-day point-prevalence abstinence
Duration of follow-up: 12 months
Biochemical validation of non-smokers: none
Identification  
Notes New for 2012 update
Source of funding: This study was supported by the National Cancer Institute (R01 CA100341) and the
Group Health Center for Health Studies in Seattle. We thank Amy Mohelnitzky, Richard Hert, MD, Ralph
Stumbo, RRT, CPFT, Rick Bloss, Zoe Bermet, Mary Shea, Lisa Shulman, Emily Westbrook, Mona Deprey,
McClure 2009 
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Free & Clear Inc., the Washington State Quitline, and the staH of the Center for Health Studies' Survey
Research Programme for their help with this research.
Declaration of interest: No financial disclosures were reported by the authors of this paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Eligible smokers were randomised to treatment using an automated randomi-
sation algorithm.
Allocation concealment
(selection bias)
Unclear risk Concealment not mentioned.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence not biochemically validated, but similar amounts of face-to-face
contact between groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data missing for 13% of participants in each group at 12 months.
McClure 2009  (Continued)
 
 
Methods Setting: large general practice, Surrey, UK
Study design: randomised controlled trial
Study grouping: parallel group
Comment: sample size based on previous research = 602
Quasi-randomisation: clinics were run in parallel at the same venue but on different weekdays for the
tests and control groups.
Study period: 2011 to 2013
Number of participants screened: 1775
Number of participants included: 109
Participants Included criteria: aged 20 to 70 years; smoking more than 10 cigarettes daily
Excluded criteria: history of major depression and other psychiatric conditions, dementias, and seri-
ous or terminal illness (cancers, etc.). Individuals on warfarin. Individuals who do not wish to have a ge-
netic test or do not wish to take part in a research study.
Recruitment setting: primary care premises of a group general practitioner practice in an English sub-
urb southwest of London
Baseline characteristics
Test group (genetic test and risk score)
• N: 36• % female: 55.6%• mean age: 49.• mean pack years: 32.0
Nichols 2014 
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• mean cigarettes/day: 18.1• mean Fagerström score: 5.3• mean salivary cotinine score: 2.5
Control group
• N: 31• % female: 53.3%• mean age: 49.0• years in education: 26.2• mean pack years: 28.9• mean cigarettes/day: 18.1• mean Fagerström score: 4.5• mean salivary cotinine score: 2.3
Interventions Intervention characteristics
Intervention: genetic test and risk score (Respiragene)
• Biofeedback: buccal swab was taken for the 20-gene test on the first or second attendance. The gene-
based test report included the risk score with an explanation of how the scores relate to the 3 different
risk categories: moderate, high, and very high.
Both groups:
• Counselling intervention: 8 weekly smoking cessation sessions including group counselling and advice
on smoking cessation pharmacotherapy (varenicline or range of NRTs)
Outcomes Smoking cessation at 6 months, validated (CO breath test and salivary cotinine)
Identification Country: UK
Setting: United Kingdom National Health Services (NHS) smoking cessation clinic
Comments: NA
Authors name: John A A Nichols
Institution: Department of Clinical and Experimental Medicine, University of Surrey, Guildford
Email: drjaan@ntlworld.com
Address: 60 Manor Way, Onslow Village, Guildford, Surrey GU2 7RR, UK
Notes Source of funding: Lab 21, Cambridge, UK; Synergenz BioScience Ltd, Evanston, IL, USA
Declaration of interest: JN and PG are in receipt of research grants from Lab 21, Cambridge, who are
marketing the Respiragene test in the UK, and Synergenz BioScience Ltd, who financed the develop-
ment of the test from its origins in New Zealand. We initially purchased SmokeScreen kits (for salivary
cotinine estimation) from GFC Diagnostics Ltd, but they subsequently supplied 30 kits free of charge.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk 2 clinics were run in parallel at the same venue but on different weekdays for
test and control groups. Participants who replied stating that they wished to
stop smoking by attending our clinic were randomised by the principal investi-
gator.
Nichols 2014  (Continued)
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Allocation concealment
(selection bias)
High risk Participants were allocated by the principal investigator.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Analyses are not intention-to-treat, and lost to follow-up excluded from analy-
ses.
Other bias Unclear risk Selective reporting = unclear: Initially defined secondary endpoints (intention
to stop smoking, cigarette consumption, uptake of invitation to cessation, ad-
herence to cessation course, and self-reported smoking cessation) not all re-
ported. Self-reported cessation also considered as primary endpoint in final
analysis.
Nichols 2014  (Continued)
 
 
Methods Setting: primary care (5 general practices, UK)
Recruitment: by letter to registered patients
Selection: not selected by motivation
Participants 561 current smokers (not defined) aged > 35, 54% female, average age 53, mean cpd: 17, 29% pre-con-
templative, 32% contemplative, 17% preparation, 21% action
Therapists: study staH member
Interventions All participants had lung function assessed by spirometry before randomisation. Strongly encouraged
to give up and given written contact details of National Health Service (NHS) smoking cessation ser-
vices. If evidence of asthma or restrictive lung disease, advised to see GP. Told they would be re-tested
at 12 months.
Intervention 1: immediate verbal feedback of lung age with explanation. Described as normal if lung
age less than or equal to chronological age.
Intervention 2: letter giving test results without lung age
Outcomes Definition of abstinence: unspecified
Duration of follow-up: 12 months
Biochemical validation of non-smokers: exhaled CO, cotinine < 14.2 ng/mL
Identification  
Notes Source of funding: Leading Practice Through Research award from the Health Foundation
Declaration of interest: None declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "A clerk (who then took no further part in the study) prepared 600 sequential-
ly numbered opaque sealed envelopes, each containing a card with allocation
group determined by computer generated random number (odd = interven-
tion)”
Parkes 2008 
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Allocation concealment
(selection bias)
Low risk “If the participant met the inclusion criteria and gave consent, he or she was
entered into the study and underwent baseline spirometry. The next num-
bered envelope in the series was then opened to determine allocation group”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Follow-up assessors blind to allocation group, biochemical validation used.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 11% lost to follow-up in each arm, included as smokers.
Parkes 2008  (Continued)
 
 
Methods Setting: US Veterans Administration Demonstration Project
Recruitment: veterans attending a health promotion clinic
Selected: responding to mailed invitations for health promotion. Some recruited at second visit.
Participants 90 smokers (not defined); mean age 53.7 years (55.5 vs 51.7), 4% female, mean cpd: 23.5, mean pack-
year: 60.4
Initial cessation intent: 51% vs 44%
Therapist: nurse-practitioner
Interventions Intervention: spirometry, exhaled CO, discussion of pulmonary symptoms + control intervention
Control: 50-minute educational intervention, review of self-help manual, invitation to a 9-session 1-
to-1 counselling programme
Outcomes Definition of abstinence: point prevalence
Duration of follow-up: 12 months
Biochemical validation of non-smokers: exhaled CO <= 10 ppm
Identification  
Notes Funding source: supported by VA Health Services Research and Development Funds
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, method not stated
Allocation concealment
(selection bias)
Unclear risk No details given.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Follow-up assessors blind to allocation group, biochemical validation used.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 13 (29%) intervention, 6 (13%) control lost to follow-up at 12 months, included
as smokers.
Risser 1990 
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Methods Setting: Department of Ambulatory Care and Community Medicine, University of Lausanne
Recruitment: newspaper advertisement (lay press) in the French-speaking part of Switzerland
Selected: smokers from the general population
Participants 536 smokers randomised (267 in the intervention group and 269 in the control group) out of 1036 par-
ticipants screened for eligibility; 265 and 267 analysed in the intervention group and control groups,
respectively; smokers defined as more than 10 cpd with no period of smoking abstinence of at least 3
months in the past year.
Mean age: 51.1 years; 43.5% female; median cpd: 20; 17 years age at initiation (median); 5.2 Fagerström
score (mean); 2 previous quit attempts (median)
Therapist: nurse
Interventions Intervention: carotid plaque screening (ultrasound) + control intervention (smokers with at least 1
carotid plaque received a 7-minute standardised brief explanation on the significance of atherosclerot-
ic plaques)
Control: brief advice for smoking cessation; 7-minute explanation on the risks associated with tobacco
smoking; 6 individual counselling sessions, 1 telephone call at 6 months, NRT patches tailored to indi-
vidual needs; brochures on smoking cessation
Outcomes Definition of abstinence: 1-week smoking abstinence (point prevalence)
Duration of follow-up: 12 months
Biochemical validation of non-smokers: exhaled CO < 10 ppm and serum cotinine level < 25 ng/mL
Identification  
Notes New for 2012 update
Source of funding: This study was supported by research grant 3200B0-116097 from the Swiss Nation-
al Science Foundation, by the Swiss Heart Foundation, by the Lausanne University Hospital Strategic
Plan, and by grant FPT 08.002282 from the Swiss Tobacco Prevention Funds, Federal Office of Public
Health.
Declaration of interest: None declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random assignment to 1 of the 2 groups using a computer-generated ran-
domisation scheme in a 1:1 ratio
Allocation concealment
(selection bias)
Low risk Sealed, opaque, sequentially numbered envelopes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 14 participants were lost to follow-up; 7 who withdrew their participation were
classified as current smokers.
Rodondi 2012 
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Methods Setting: 11 UK general practices
Recruitment: screening of all outpatients
Selected: outpatients plus made appointment for health check
Participants 751 participants out of 4330 identified smokers (self-defined)
Mean age 38.5 years. Other characteristics not mentioned.
Therapist: practice nurse
Interventions Intervention: exhaled CO measure plus discussion of significance plus control intervention
Control: counselling by practice nurse plus written material given plus offer of a follow-up appoint-
ment
Outcomes Definition of abstinence: point prevalence
Duration of follow-up: 12 months
Biochemical validation of non-smokers: urinary cotinine for sample, cut-oH not reported Outcomes
used are self-report.
Identification  
Notes Sources of funding: We are grateful to the doctors, nurses, receptionists and others in the practices
participating in this study, to Elaine Fullard for her advice, to Valerie Stone for clerical assistance, and
to the department of preventive medicine at St Bartholomews Hospital for performing the cotinine as-
says. We also thank the British Heart Foundation and Health Education Authority for financial support.
David Mant and Lesley Jones are supported by the Imperial Cancer Research Fund.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Randomised by day of attendance on a 1:2 basis. Desktop card reminding doc-
tors of right allocation. 120 wrongly allocated participants, excluded from fur-
ther analysis. Second step randomised health check attenders for the CO inter-
vention, method not described
Allocation concealment
(selection bias)
High risk First-stage randomisation had potential for selection bias; only attenders eligi-
ble for second stage, no information on concealment at this stage.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used only for a sample, results used in analysis not vali-
dated, but similar amounts of face-to-face contact between groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 63.8% followed up, but percentage by group not provided; unclear if differen-
tial attrition present. Non-responders included as smokers.
Sanders 1989 
 
 
Methods Setting: 44 general practices, Italy
Recruitment: screening of outpatients on specific days
Selected: outpatients
Participants 923 included out of 1009 screened. Smoker definition not given. Age: 20.1% < 31 years; 28.0% 31 to 40
years; 26.8% 41 to 50 years; 25.0% > 50 years. 38% female, cpd: 16.7% <= 10 cpd; 55.2% 11 to 20 cpd;
28.1% > 20 cpd. 51% reporting symptoms.
Therapist: physician
Segnan 1991 
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Interventions Intervention: spirometry prescription plus control intervention
Control: repeated counselling with reinforcement sessions
(2 other groups not used in our comparison: minimal intervention and repeated counselling plus nico-
tine gum)
Outcomes Definition of abstinence: 7 days abstinence
Duration of follow-up: 12 months
Biochemical validation of non-smokers: urinary cotinine < 100 ng/mg
Identification  
Notes In the intervention group, 124 participants out of 292 reported having a spirometry test.
Funding sources/declaration of interest: Serono SPA provided the nicotine gum used in the study.
The Anti-Smoking Committee of the Municipality, Torino, and ACI (Automobile Club Italiano) also
helped in various ways.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised; "blocked treatment allocation was based on a sequence of ran-
dom numbers"
Allocation concealment
(selection bias)
Low risk "Closed, numbered envelopes"; "The envelopes were indistinguishable from
the outside"; "The research staH checked physicians' compliance with the pro-
cedure for assignment by comparing envelope numbers and dates of recruit-
ment."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 13% lost to follow-up at 12 months, included as smokers
Segnan 1991  (Continued)
 
 
Methods Setting: Laboratory at University College London (research institution)
Recruitment: smokers were recruited from the general population through advertisements in local
newspapers, flyers, e-mails, posters on public bulletin boards at and around University College London
Selected: smokers who responded to the advertisements
Participants 160 smokers (> 5 cpd for the past year) aged between 18 and 35 years, 43.7% female, average age 31.7
years, mean cpd: 13.8
Therapists: postdoctoral researchers
Interventions Intervention: expired air CO level + generic leaflet about lung disease + brief targeted feedback about
their CO levels in relation to the development of cardiovascular and respiratory diseases
Control: expired air CO measurement (results not shown) + generic leaflet about lung disease + stan-
dardised brief advice to quit smoking
Outcomes Definition of abstinence: 7-day point-prevalence abstinence
Duration of follow-up: 6 months
Biochemical validation of non-smokers: none
Shahab 2011 
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Identification  
Notes New for 2012 update. Participants received an incentive of GBP 50 for their time.
Source of funding: This study was funded by the Department of Health and the charity Cancer Re-
search United Kingdom. These bodies bear no responsibility for the design and conduct of the study;
collection, management, analysis, and interpretation of the data; and preparation, review, or approval
of the manuscript. We thank Erdem Pulcu and Onupama Roy for their help with collecting data for this
study.
Declaration of interest: Lion Shahab has received an honorarium for a talk and travel expenses from
Pfizer. Robert West undertakes research and consultancy for the following developers and manufactur-
ers of smoking cessation treatments; Pfizer, J7J, McNeil, GSK, Nabi, Novartis and Sanofi-Aventis. Robert
West also has a share in the patent of a novel nicotine delivery device.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random number-generated group allocation. No description about the ran-
dom sequence generation
Allocation concealment
(selection bias)
Unclear risk Sealed envelope containing the random number-generated group allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence not biochemically validated. Participants were contacted by a
researcher blinded to group allocation to complete the follow-up. Similar
amounts of face-to-face contact between groups
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Similar numbers lost to follow-up in both groups (23/79 control, 28/81 inter-
vention - reason given for all: "could not be contacted"). All lost to follow-up
included as smokers in analysis.
Shahab 2011  (Continued)
 
 
Methods Setting: 2 primary care clinics, USA
Recruitment: all smokers among outpatients
Selected: outpatients
Participants 205 included out of 360 smokers (self-defined); mean age 38.5 years, 62.5% female, mean cpd: 20.0,
mean pack-years: 28.9. Stage of change: 36% in preparation stage
Therapist: study staH
Interventions Intervention: spirometry and exhaled CO + control intervention
Control: counselling according to transtheoretical model stage + written material + NRT encouraged if
prepared to stop
Outcomes Definition of abstinence: sustained quitting rate
Duration of follow-up: 9 months
Biochemical validation of non-smokers: none
Identification  
Notes Source of funding: This project was funded by the American Lung Association of Oregon and the Amer-
ican Academy of Family Practice.
Sippel 1999 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Pseudo-randomised; questionnaires numbered consecutively, and partici-
pants enrolled in chronological order based on time of check-in. Odd num-
bered = intervention
Allocation concealment
(selection bias)
High risk Not concealed, potential selection bias, although nurses performing partic-
ipant check-in were blinded to the questionnaire numbers. "As 4 to 6 nurses
conducted patient check-in independently and simultaneously at each clinic,
it is unlikely that any given patient would be preferentially enrolled into either
study arm."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Follow-up assessors blind to allocation group. No biochemical validation used,
but similar amounts of face-to-face contact between groups.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 18.6% intervention and 12.6% control lost to follow-up, included as smokers.
Sippel 1999  (Continued)
 
 
Methods Setting: "stop-smoking clinic", USA
Recruitment: public service announcement + media advertising
Selected: those responding to advertising, paying USD 45
Participants 64 out of 141 eligible (self-defined smokers)
Mean age: 35.5 years, 59% female, mean cpd: 29.2, mean 3.4 previous quit attempts
Therapist: first author
Interventions Intervention: exhaled CO and spirometry feedback plus Taste Satiation (TS) (in 50%) or Focused Smok-
ing (FS) (in 50%) and booster sessions for half of each subgroup
Control: 50% TS sessions or 50% FS sessions, booster sessions for half of each subgroup
Outcomes Definition of abstinence: 10 days abstinence
Duration of follow-up: 6 months
Biochemical validation of non-smokers: exhaled CO < 8 ppm
Identification  
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised in 2x2x2 factorial design, method not described
Allocation concealment
(selection bias)
Unclear risk No details given.
Blinding of outcome as-
sessment (detection bias) 
Low risk Abstinence biochemically validated
Walker 1985 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Only participants reached at 6 months included in analysis. "Five subjects
dropped out of treatment and 3 additional subjects were randomly eliminated
to facilitate data analysis."
Walker 1985  (Continued)
CO: carbon monoxide
COPD: Chronic Obstructive Pulmonary Disease
cpd: cigarettes per day
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
ICMJE: International Committee of Medical Journal Editors
IDU: injecting drug user
NRT: nicotine replacement therapy
ppm: parts per million
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Anthonisen 1994 Effect of spirometry cannot be isolated. Spirometry performed in all participants. Randomisation
to 3 groups: smoking intervention (12-session programme) + bronchodilatator, smoking interven-
tion + placebo, no intervention
Ashraf 2014 Cannot isolate effect of biofeedback
Barnfather 2005 Only 8 weeks follow-up. Intervention was immediate feedback from a point-of-care test for salivary
nicotine metabolites.
Borrelli 2002 Effect of CO cannot be isolated. No results available.
Intervention: Precaution Adoption Model: CO feedback + environmental tobacco smoke to the
child feedback + motivational counselling
Control: Behavioral Action Model: self efficacy-enhancing counselling
Borrelli 2005 Effect of CO cannot be isolated.
Intervention: motivational interviewing and CO feedback
Control: standard care
Borrelli 2010 Feedback about secondhand CO in asthmatic children of the participants. Too-short follow-up (3
months)
ChiCTR-TRC-13003255 Trial not completed.
Cope 2003 Not a true randomised trial
Cox 2003 No control group. All participants received chest CT scan screening for lung carcinoma.
Ferketich 2012 Effect of CT scan on the motivation to quit cannot be isolated.
Foulds 2015 No measure of smoking cessation at 6 months
Frank 1999 Full text not available.
Intervention: urinary cotinine feedback to prenatal patients
Gulliver 2008 Spirometry was not used to give feedback on lung function.
Hajek 2001 Effect of CO cannot be isolated.
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Study Reason for exclusion
Intervention: counselling, written materials, CO
Control: standard antismoking leaflets
Hajek 2002 Effect of CO cannot be isolated.
Intervention: CO feedback, booklet, quiz, "buddy", declaration of commitment to give up, sticker in
patient's notes
Control: verbal advice + different booklet
Humerfelt 1998 Effect of spirometry cannot be isolated.
Intervention: spirometry + written counselling + pamphlet
Control: spirometry
Kaminsky 2011 Follow-up at 1 month only
Kanner 1996 Effect of spirometry cannot be isolated. Spirometry performed in all participants. Randomisation
to 3 groups: smoking intervention (12-session programme) + bronchodilatator, smoking interven-
tion + placebo, no intervention
Kanner 1999 Effect of spirometry cannot be isolated. Spirometry performed in all participants. Randomisation
to 3 groups: smoking intervention (12-session programme) + bronchodilatator, smoking interven-
tion + placebo, no intervention
Kotz 2009 Effect of spirometry feedback cannot be isolated. Intervention group received spirometry/COPD
feedback but also an intervention to challenge irrational beliefs about smoking. They were further
instructed to use a smoking cessation diary to monitor smoking behaviour and beliefs about smok-
ing. The latter interventions were not offered to the control group.
Lipkus 2007 Outcomes were perceived smoking-related health risks, worries, and desire to quit, not smoking
cessation.
Marteau 2012 Study of behavioural impact of pharmacogenomics. Outcome was adherence to smoking cessa-
tion medication. Measures effect of informing smokers of genetic test results on responsiveness to
smoking cessation medication
Martucci 2010 Effect of bronchoscopy results on smoking cessation cannot be isolated.
McBride 2002 Effect of genetic biomarker feedback cannot be isolated.
Intervention: feedback on glutathione-S-transferase M1 (GSTM1) + 4 phone calls + control interven-
tion
Control: self help manual +/- NRT. No phone calls
McClure 2013 No measure of smoking cessation at 6 months
McIntosh 1994 Smoking cessation is not considered as an outcome.
Mols 2015 Cannot isolate effect of biofeedback
NCT00862368 Cannot isolate effect of biofeedback
NCT00991081 No measure of smoking cessation at 6 months
NCT01145729 No measure of smoking cessation at 6 months
NCT02206971 No measure of smoking cessation at 6 months
NCT02837809 Wrong intervention
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Study Reason for exclusion
NCT02922790 No measure of smoking cessation at 6 months
Nuesslein 2006 Only 6 weeks' follow-up
Intervention: notification of urine cotinine levels + control
Control: written advice to quit from a paediatrician
Ojedokun 2013 No measure of smoking cessation at 6 months
Paek 2014 Wrong intervention
Pistelli 2007 Conference abstract. Post hoc analysis
Intervention: participation in a lung cancer screening + control
Control: biofeedback (lung CT) + smoking cessation programme
Powers 2011 Only 3 months' follow-up. Coronary heart disease risk communication. Participants were smokers
and non-smokers (being a smoker was not a criterion for inclusion).
Prokhorov 2008 Effect of the health feedback (expired CO) cannot be isolated. The aim of the study was to compare
standard care with computer-assisted care.
Rennie 2012 Participants assigned to hypothetical risk scenarios; outcome was motivation, not cessation.
Richmond 1986 Effect of biomarker feedback cannot be isolated. Spirometry, blood CO, urinary cotinine in both
groups.
Intervention: 4 visits and discussion of manual
Rodriguez 2011 Effect of biomarker feedback cannot be isolated.
"Both arms will receive brief structured advice and a detailed discussion of the spirometry
results at visit 0. The control group will only be given brief structured advice about giving up smok-
ing on the follow up"
Sanderson 2005 Short-term study of effect of genetic testing for lung cancer susceptibility. Follow-up at 10 weeks.
Main outcomes were motivation to quit, perceived risk, depression and anxiety.
Sanderson 2007 Hypothetical scenario tested (not real life)
Sanderson 2008 Follow-up too short (2 months)
Sejourne 2010 No measure of smoking abstinence at 6 months or later after the start of the intervention
Shahab 2007 Pilot study of visual personalised biomarker feedback with follow-up at 4 weeks. Main outcomes
were perception of susceptibility, engagement in cessation behaviours, and intentions to stop.
Shi 2013 Wrong intervention
Shoptaw 2002 Effect of CO feedback cannot be isolated.
CO feedback given to all groups. 2x2 design:
1. relapse-prevention counselling + NRT
2. contingency management: vouchers given for validated abstinence + NRT
Control: NRT
Stotts 2009 Assessments at baseline (16 to 26 weeks of gestation) and at the end of pregnancy. Too-short fol-
low-up
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Study Reason for exclusion
Stratelis 2006 Not a true randomised trial, no control without biomedical risk assessment. Smokers with normal
lung function at baseline received different frequencies of spirometry (annually or in 3 years).
Tammemagi 2014 Wrong study design
Taylor 2007 No control group. Study of impact of screening on smoking cessation and readiness to stop smok-
ing among participants in trials of lung screening
Terazawa 2001 Effect of biomarker feedback (CO and urinary cotinine) cannot be isolated, combined with 1 coun-
selling session and 4 follow-up calls.
Townsend 2005 No control group. Longitudinal study of smoking behaviour in people receiving lung cancer screen-
ing
van der Aalst 2011 Post hoc analysis. Current and former smokers. Screening of lung cancer by low-dose thoracic CT in
intervention arm. Only positive or indeterminate test results (lung nodules) were managed accord-
ing to a protocol (feedback was not standardised, and not about smoking cessation but lung can-
cer).
Wakefield 2002 Biomarker feedback given on the health of the participant's child, not on the participant's own
health. The motivational component here differs from the approach in the other included studies.
Warner 2012 Long-term abstinence not an outcome. CO levels were measured preoperatively.
Wilt 2007 Review
Wright 2006 Outcome was motivation to quit based on hypothetical risk information.
Zullig 2014 No measure of smoking cessation at 6 months
CO: carbon monoxide
COPD: chronic obstructive pulmonary disease
CT: computed tomography
NRT: nicotine replacement therapy
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised controlled trial with parallel assignment (triple-blinded)
Participants 822 participants aged 21 years and older
Inclusion criteria:
1. Adult (>= 21 years of age), seeking treatment for smoking cessation
2. Able to speak English
3. Active smoking (cigarettes per day >= 5) and exhaled carbon monoxide >= 8 ppm
4. Agree to participate in this randomised smoking cessation trial with follow-up assessments up to
12 months
Exclusion criteria:
1. Pregnancy or breastfeeding
2. Active use or recent use (< or equal to 1 month) of medication or e-cigarettes for nicotine depen-
dence/smoking cessation, or use of e-cigarettes for more than 9 days in the prior month
NCT02351167 
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3. Allergy to nicotine patch, lozenge, or varenicline
4. Unwillingness to prevent pregnancy during the medication phase and 1 month afterwards
(women only)
5. Significant cardiac conditions (myocardial infarction, unstable angina, coronary angioplasty, car-
diac bypass) or serious arrhythmia in past 6 months
6. Current heavy alcohol consumption (>= 6 drinks/day, 6 days/week)
7. Active psychosis or poorly controlled depression within the past 6 months
8. Any prior suicide attempt or suicidal ideation within the past 6 months
9. End-stage renal disease with haemodialysis
Interventions The investigators propose a prospective, genotype-based stratified randomisation trial to compare
2 smoking cessation medications (combination NRT (patch and lozenge), varenicline vs placebo)
for 3 months in 720 smokers with known genotypes.
Outcomes Primary outcome measures
1. 7-day point-prevalence quit rate (Time Frame: Week 12). The definition of this measure requires:
a. no self-reported smoking (not even a puH of a cigarette) for at least the 7 days prior to the
assessment; and
b. biochemical verification of abstinence.
Secondary outcome measures
1. Continuous abstinence (Time Frame: 12 weeks (with first week initial grace period)). The definition
of this measure requires: not taking even 1 cigarette puH from target quit date to end of treatment.
2. 7-day point-prevalence quit rate (Time Frame: Week 24). The definition of this measure requires:
a. no self-reported smoking (not even a puH of a cigarette) for at least the 7 days prior to the
assessment; and
b. biochemical verification of abstinence.
Notes 7-day point-prevalence abstinence at 6 months should be available. Genotype-based randomisa-
tion, but apparently no biofeedback
NCT02351167  (Continued)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Effectiveness of quit smoking motivation with carbon monoxide feedback module (COQUIT)
among college smoker in Selangor
Methods Single-blinded cluster-randomised controlled trial at 10 tertiary colleges
Participants 160 students at Community College in Selangor, Malaysia
Interventions Standard brief 5R motivational strategy and an additional CO motivational feedback module. Ex-
pired carbon monoxide is measured by the principal investigator on a 1-to-1 basis. The CO reading
is recorded directly into the iPad (using a mobile phone application) together with explained feed-
back about the result and interpretation. The result of the CO is then e-mailed to the participants.
Participants in the control group only receive the standard brief 5R motivational strategy.
Outcomes Primary: stage of changes based on the Transtheoretical Model that will be measured using validat-
ed questionnaire at 1, 3, and 6 months postintervention
Secondary: any quit attempt defined as 24 hours of not smoking, number of cigarettes smoked per
day, and smoking habit at 1, 3, and 6 months
ACTRN12618000291280 
Biomedical risk assessment as an aid for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
52
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Starting date Anticipated 16 April 2018
Contact information Dr Muhammad Adil Zainal Abidin
adilzainal@gmail.com
Notes  
ACTRN12618000291280  (Continued)
 
 
Trial name or title Effectiveness of spirometry as a motivational tool for smoking cessation based on health belief
model
Methods Single-blinded, parallel-group randomised controlled trial
Participants 160 participants
Inclusion criteria: patient satisfaction; smoking history at least 10 pack/year; lack of non-cigarette
related pulmonary disease; new spirometry test; ages between 20 and 90 Exclusion criteria: patient
dissatisfaction
Interventions Intervention group: participants will attend a speech meeting to increase information about ciga-
rettes and make them susceptible to smoking cessation. At this meeting, educational pamphlets
will be distributed on health, economic, and social disadvantages. Then an individual motivational
educational counselling exercise will be carried out for each participant, with an emphasis on test-
ing the spirometry of the participant and comparing it with spirometry of a healthy person of the
same age and sex, and providing relevant statistics. In the next step, the intervention group will be
divided into groups of 10, discussing the benefits and barriers to smoking cessation in the group
discussion. Then the questionnaire will be filled by self-reporting to determine the perceived sensi-
tivity, perceived severity, perceived benefits, and perceived barriers. At intervals at the end of the
second week, 3 and 6 months, information about the rate of smoking cessation will be collected
using the follow-up questionnaire.
Outcomes "Action to smoking cessation"? at 2 weeks, 3 months and 6 months
"keep smoking cessation"? at 2 weeks, 3 months and 6 months
Starting date 20 March 2016
Contact information Saeid Ghasemian
ghasemian@shmu.ac.ir
Notes  
IRCT2017080435257N1 
 
 
Trial name or title Effectiveness of Smoking Cessation Advice Combined With Spirometric Results in Adult Smokers
(ESPITAP)
Methods Randomised controlled trial, parallel assignment, single-blinded (participants)
Participants 596 participants
Inclusion criteria:
Martin Lujan 2011 
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• Adult smokers aged between 35 and 70 years
Exclusion criteria:
• Antecedents of any respiratory disease• Suffering from any chronic or terminal disorder• Counterindication to undertake spirometry or that may hinder the performance of the spirometry
test
Interventions Intervention arm: spirometry and smoking cessation advice. Participants will be given a brief but
structured smoking cessation advice (according to the standards of the Tobacco Study Group of
the Catalan Society of Family Medicine) together with a detailed and structured discussion of the
spirometric results.
Control arm: smoking cessation advice. Brief but structured smoking cessation advice (according
to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
Outcomes Smoking abstinence: self-reported abstinence (12 or more months). Time Frame: 12 months
Smoking abstinence confirmed by an expired air carbon monoxide
Starting date June 2008
Contact information Principal Investigator: Francisco Martín-Luján, MD, Catalan Institute of Health
Notes Last update posted on ClinicalTrials.gov: 7 April 2011
Authors contacted but no answer received.
Martin Lujan 2011  (Continued)
 
 
Trial name or title Multicentric Randomized Clinical Trial to Evaluate the Long-term Effectiveness of a Motivational In-
tervention Against Smoking, Based on the Information Obtained From Spirometry in Primary Care.
(RESET-ESPITAP2)
Methods Randomised controlled trial, parallel assignment, open-label
Participants 1100 participants
Inclusion criteria:
• Active smokers (consumption > 10 packs/year)
Exclusion criteria:
• Active respiratory disease• Practice of a spirometry during prior 12 months• Suffering from any chronic or terminal disorder• Counterindication to undertake spirometry or that may hinder the performance of the spirometry
test
Interventions Intervention arm: spirometry. Will be given brief but structured smoking cessation advice (accord-
ing to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) togeth-
er with a detailed and structured 20-minute visit with details of the spirometry data (values of res-
piratory capacity and volumes referring on the theoretical)
Martin Lujan 2016 
Biomedical risk assessment as an aid for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
54
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Control arm: brief smoking cessation advice. Will be given brief but structured smoking cessation
advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family
Medicine)
Outcomes Cessation of tobacco consumption at 12 months. Time Frame: 12 months
Starting date November 2011 (estimated study completion date: November 2014)
Contact information Principal Investigator: Antoni Santigosa-Ayala, MD, Catalan Institute of Health
Notes Last update posted on ClinicalTrials.gov: 2 June 2014
Authors contacted but no answer received. Protocol published in 2016, but no results published.
Martin Lujan 2016  (Continued)
 
 
Trial name or title A pilot randomized controlled trial on the effectiveness of a 'lung age' intervention on smoking ces-
sation.
Effectiveness of a 'lung age' intervention on smoking cessation rate in a Singaporean community
Methods Pilot randomised controlled trial
Participants 108 participants (convenience sample) recruited from population health screenings in Singapore
Inclusion criteria:
• Currently smoking• Aged 35 years and above• Able to read and/or speak in English and/or Mandarin
Exclusion criteria:
• Known history of major psychiatric illness• History of respiratory-related diseases: COPD, asthma, bronchiectasis• Ejection fraction < 4%, or diagnosed with congestive cardiac failure• Diagnosed with acute myocardial infarction within 1 month• Diagnosed with fluid overload/acute pulmonary oedema• Receiving oxygen therapy• Recent eye/thoracic/abdominal surgery• Chest/abdominal/oral and facial pain• Hyperventilation syndrome
Interventions Intervention arm: lung age intervention
A spirometry test will be conducted to determine the lung age of participants in the intervention
group. These participants will then receive an educational intervention on their lung age in addi-
tion to standard smoking cessation counselling.
Control arm: usual smoking education
Outcomes Smoking cessation rates at 3 and 6 months
Starting date 4 September 2014 (end date 3 September 2015)
Contact information Wenru Wang, PhD, RN
Muhammad 2015 
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nurww@nus.edu.sg
Notes Study completed but data not published.
Author contacted but no answer received.
Muhammad 2015  (Continued)
 
 
Trial name or title Developing genetic education for smoking cessation
Methods Randomised controlled trial with parallel assignment, open-label
Participants 103 participants.
Inclusion criteria:
• Current smoker• Smoking 10 or more cigarettes per day• 19 years of age or older• Intention of quitting smoking in the next month• Agree to use 2 forms of acceptable birth control while using the nicotine replacement patch
Exclusion criteria:
• Not currently seeking treatment for a mental disorder with psychotic symptoms• Not currently pregnant or nursing• Not been recently diagnosed or currently affected with cancer or any other life-threatening illness• No recent heart attack• No history of high blood pressure or not currently receiving treatment to manage high blood pres-
sure• No history of an irregular heartbeat• Not currently taking medications to help quit smoking (i.e. varenicline (Chantix), bupropion (Zy-
ban, Wellbutrin), NRT)• No history of adverse effects from using nicotine replacement patches• Not currently experiencing serious pain or discomfort due to heart disease
Interventions Experimental: Genetic Education Session (GES)
The intervention includes receiving education about genetics and smoking. The content is basic
genetics and education about the multifactorial nature of smoking; research findings about genet-
ic contributions to smoking, potential applications of this research for cessation treatment, and le-
gal, ethical, and social implications of future use of genotyping for cessation. All participants also
receive a 5-week standard cognitive-behavioural smoking cessation intervention with 6 weeks of
over-the-counter transdermal nicotine replacement therapy.
Active comparator: Nutrition Education Session (NES)
To control for an attention placebo effect, the control group will receive information about nutri-
tional guidelines as established by the US Department of Agriculture (USDA) and the US Food and
Drug Administration. The attention control group will be referred to as the Nutritional Education
Session (NES) group. The content of NES sessions 1 and 2 are use of the USDA (MyPyramid) dietary
and food safety guidelines. All participants also receive a 5-week standard cognitive-behaviour-
al smoking cessation intervention with 6 weeks of over-the-counter transdermal nicotine replace-
ment therapy.
Outcomes Smoking-related behaviour when experimental and attention control groups are compared. Time
Frame: 6 months after the end of the Smoking Cessation Intervention
NCT01186016 
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Use of cessation strategies, abstinence, and interest in genotyping
Starting date February 2010
Contact information Professor Julia Houfek, PhD, APRN-CNS, University of Nebraska
Notes Last update posted on ClinicalTrials.gov: 21 January 2013
Authors contacted but no answer received.
NCT01186016  (Continued)
 
 
Trial name or title Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) -
Phase 3 Pilot Clinical Trial
Methods Randomised controlled trial, parallel assignments, open-label
Participants 60 participants
Inclusion criteria:
• Alaska Native• 18 years of age or older• Provide written informed consent• Be currently pregnant and at < 24 weeks gestation• Reside in Anchorage and plan to deliver at the ANMC• Current tobacco user defined as any use of iqmik, commercial smokeless tobacco, and/or ciga-
rettes during the past 7 days
Exclusion criteria:
• Use of nicotine replacement therapy or medications for tobacco cessation or participation in a
behavioural cessation programme within the past 30 days• Another woman from the same household has enrolled
Interventions Experimental: biomarker feedback intervention (phone-based smoking cessation counselling).
Feedback on maternal cotinine and likely infant NNAL. Phone-based behavioural smoking cessa-
tion counselling
Active comparator: control condition (phone-based smoking cessation counselling).
Phone-based behavioural smoking cessation counselling
Outcomes Smoking abstinence in late pregnancy (self-reported abstinence verified with cotinine). Time
Frame: at week 36 gestation or greater up to the time of delivery
Self-reported abstinence verified with cotinine.
Starting date March 2015 (study completion date 2017)
Contact information Christi A Patten, PhD, Mayo clinic
Notes Last update posted: 19 December 2017
No data published, author contacted but no answer received.
NCT02431611 
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Trial name or title Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)
Methods Single-blind (participants) randomised trial with factorial assignment (2 interventions)
Participants 276 adults 50 years of age and older
Inclusion criteria:
• Current smoker• 20 pack/year smoking history• Eligible for the Smilow treatment programme• Willing to enrol in smoking cessation programme• Willing to be randomised in smoking cessation study• English speaking
Exclusion criteria:
• Dementia or current serious psychiatric or unstable medical illness• Pregnancy or breastfeeding• Known fat malabsorption diseases that may affect skin carotenoid status
Interventions The purpose of this study is to test the efficacy of 2 separate, sequential interventions to promote
tobacco cessation/reduction in individuals who are screened for lung cancer or who are eligible for
lung cancer screening. Each intervention will be compared to standard of care. The first interven-
tion will be a personalised-message intervention; the second intervention will consist of a biofeed-
back-based intervention.
The aim of the second intervention is to evaluate the efficacy of a novel, biofeedback-based inter-
vention that provides personalised individual-level feedback on biomarkers of lung cancer risk
and how they improve in response to cessation, delivered in a gain-framed way. The biomarkers
include skin carotenoid status, spirometry, and plasma bilirubin, all of which improve with cessa-
tion. The study team will examine whether the biofeedback prevents relapse in those who quit and
leads to reductions in smoking in lung nodule patients who failed to quit.
Outcomes Primary outcome:
1. Smoking cessation (Time Frame: 8 weeks). Smoking cessation will be measured by self-report and
validated by the study team using CO levels. CO will be measured.
2. Number of cigarettes smoked (Time Frame: 6 months). Number of cigarettes smoked will be as-
sessed by self-report. Smoking cessation will be measured by self-report and validated by the
study team using CO levels. CO will be measured.
Secondary outcomes
1. Smoking cessation (Time Frame: baseline, 4 weeks, 3 months). Smoking cessation will be mea-
sured by self-report and validated by the study team using CO levels. CO will be measured.
Starting date January 2016
Contact information Brenda Cartmel, PhD
brenda.cartmel@yale.edu
Notes Unclear whether 6-month smoking cessation outcome will be available
NCT02658032 
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Trial name or title Smartphone App and CO Self-monitoring for Smoking Cessation (SMART-CO)
Methods Parallel-group, open-label randomised controlled trial
Participants 510 participants, 16 years of age and older
Inclusion criteria:
• HIV-infected smokers 16 years and older smoking 3 cigarettes per day enrolled into the Swiss HIV
Cohort Study• Willingness to quit smoking• Speaking 1 or more of official Swiss national languages or English users of smartphone (specifi-
cally iPhone 5, 5c, 5s, 6, 6+ running iOS version 8.0+; smartphones with resolution of at least 800
x 400 pixels running Android version 5.0+; and Android smartwatches)• Informed consent
Exclusion criteria:
• Limitations in hearing, comprehension, or vision problems that preclude full study participation• Participants with a life expectancy of less than 12 months due to any serious medical condition
Interventions The app offers a coaching function where users receive personalised messages to encourage smok-
ing cessation and advice for behavioural changes. For the first 4 weeks of the intervention, indi-
viduals will also be asked to blow daily into a breath carbon monoxide monitor before going to
sleep. Depending on the results of the breath test, individualised messages will be delivered by the
Smokelyzer feedback app to either enhance maintenance of abstinence or to increase the moti-
vation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at
least twice a week until the end of the 6-month study. The app will react with positive feedback in
individuals doing well with smoking cessation and messages to encourage individuals with difficul-
ties quitting smoking.
Outcomes Primary outcome measures:
Self-reported abstinence biochemically verified by a carbon monoxide test in-person. (Time Frame:
6 months)
Secondary outcome measures:
Differences in the number of daily cigarettes smoked from baseline to 6-month follow-up and point
prevalence of abstinence (i.e. no smoking in the past 7 days) at 6-month follow-up. (Time Frame: 6
months)
Starting date 1 June 2017
Contact information Dmitry Gryaznov
dmitry.gryaznov@usb.ch
Notes Estimated study completion date: 1 July 2019
NCT02840513 
 
 
Trial name or title Combined bio- and neuro- feedback vs. varenicline use for smoking cessation
Methods Randomised, parallel-group, open-label trial
Participants 140 participants:
NCT02991781 
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Inclusion criteria:
• Being continuous tobacco smokers (> 10 cigarettes per day) for at least 6 months• Being unemployed for at least 3 months• Being diagnosed with asthma• Being diagnosed with COPD• Age < 35, for the group of young unemployed• Age > 35 years, for the groups of asthma and COPD patients
Exclusion criteria:
• Diagnosed neurological, mental, or psychiatric illness• Drug-resistant epilepsy
Interventions This study will develop and experimentally test the efficiency of a neurofeedback (NF) training pro-
tocol for smoking cessation. As non-pharmacological, non-invasive, and painless brainwave tech-
nique, NF contributes to teach individuals how they can take control of their mind through operant
conditioning. NF regulates brain function in a natural way. The protocol will consist of 5 sessions of
skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will con-
sist of Alpha-Theta ratio up-training. The aim of the training is to reach a cross-over state, were ini-
tially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This
state is associated with a reverie and disidentification with problems, stress, or traumatic experi-
ences. Participants will therefore will learn how to increase their Theta/Alpha ratio.
The neurofeedback intervention will be compared with a different group of participants receiv-
ing an intervention based on varenicline use for approximately 3 months. The electrophysiological
evaluation of the efficacy of the intervention will include EEG resting state and a sleep polysomnog-
raphy measurement. Questionnaires and clinical evaluation include the same measurements as
the neurofeedback intervention but only at 3 time points: prior, during, after the completion of the
study.
Outcomes Standardised percentage of participants that give up smoking (Time Frame 2 years)
Starting date January 2017
Contact information Professor Panos Bamidis
bamidis@auth.gr
Notes Not sure if it will be possible to isolate the effect of biofeedback
NCT02991781  (Continued)
 
 
Trial name or title Effectiveness of the spirometry test as a motivational tool for quitting tobacco in primary care
Methods Randomised controlled trial, parallel assignment, open-label
Participants 90 participants
Inclusion criteria:
• An active smoker• Aged between 40 and 75 years• No diagnosis of acute or chronic respiratory disease
Exclusion criteria:
• Serious or terminal diseases
NCT03377738 
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• Limiting osteoarticular diseases• Serious mental diseases: psychosis• Serious depressive disorder• Neurosis• Addiction to drugs/alcohol• Displaced patients (not habitual residents)• Pregnancy• Spirometry carried out for any reason in the year prior to inclusion in the study
Interventions Intervention: diagnostic test: spirometry
All participants will be given an intervention for tobacco cessation that will depend on the individ-
ual's cessation phase and will be given a spirometry test as a motivational element for dishabitua-
tion.
Control: no intervention: antismoking therapy
All participants will be given only an intervention for tobacco cessation that will depend on the in-
dividual's cessation phase.
Outcomes 1. Number of cessations of the tobacco habit (%) (Time Frame: 2 to 3 weeks, 3 months and 6 months)
2. Cessation phase of the tobacco habit (%) (Time Frame: 2 to 3 weeks, 3 months and 6 months)
Starting date May 2011
Contact information A Lopez-santiago, MD
Notes Last update posted on ClinicalTrials.gov: 17 December 2017
Authors contacted but no answer received.
NCT03377738  (Continued)
 
 
Trial name or title PRecision Interventions for SMoking in the SCCS (PRISM-SCCS)
Methods Single-blinded randomised trial with parallel groups
Participants 68 participants
Inclusion criteria:
• Daily smoker of >= 5 cigarettes per day• Enrolled participant of the Southern Community Cohort Study (SCCS) who completed a prior sur-
vey indicating they were willing to be contacted regarding a smoking cessation clinical trial• Residence in Tennessee or Mississippi• Has stored blood sample with the SCCS• Has established primary care provider• Medically eligible and willing to take varenicline and NRT
Exclusion criteria:
• Currently taking medication to quit smoking• Enrolled or planning to be enrolled in another smoking cessation programme• Inability to give informed consent or participate due to cognitive disorder (e.g. dementia, severe
intellectual disability)
NCT03521141 
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• Unstable psychiatric illness (emergency room or hospitalised for psychiatric condition in past 6
months, change in psychiatric medications in past 3 months, or suicidal ideation in past 6 months)• Not able to send or receive mail• No access to a telephone or inability to communicate by telephone• Unable to speak and read English• History of seizures or Buerger's disease• Currently pregnant or breastfeeding
Interventions 3 intervention arms (only arm 3 (group 2) is provided with biofeedback)
1. Guideline-based care (GBC)
GBC participants are 1) referred to the state quitline, 2) provided the National Cancer Institute
Clearing the Air smoking cessation programme, and 3) asked to talk to their healthcare provider
about potential lung cancer screening. Medication assignment is guided by standard guidelines
and a conversation between the study tobacco counsellor and the participant. Groups 1 and 2 also
receive GBC counselling.
2. Active comparator:
Nicotine metabolite ratio (PC-NMR)
Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
3. Active comparator: Respiragene (PC-Respiragene)
Group 2, genetically informed lung cancer risk score. Medication assignment is guided by standard
guidelines and a conversation between the study nurse and the participant.
Outcomes Primary outcome measures:
Intervention Feasibility: ability to retain participants. Time Frame: 6 months. Feasibility of deliver-
ing precision care interventions in the SCCS, as evidenced by ability to recruit, engage, and retain
participants through the end of the study.
Secondary outcome measures:
Cessation History - Quit attempts (Time Frame: 6 months) Quit attempt (yes/no)
Cessation History - Medication use (Time Frame: 6 months) Medication use (duration of use)
Cessation History - Quitline (Time Frame: 6 months) Self-reported quitline utilisation
Cessation History - Self-reported abstinence (Time Frame: 6 months) Self-reported abstinence
Cessation History - Validated abstinence (Time Frame: 6 months) Biochemically verified (salivary
cotinine, >= 10 ng/mL) abstinence
Starting date 18 May 2018
Contact information Hilary Tindle, Associate Professor of Medicine, Vanderbilt University Medical Center
Notes  
NCT03521141  (Continued)
 
 
Trial name or title Tobacco intensive motivational and estimate risk
Methods Randomised, open-label, prospective study
Participants 204 participants, aged 40 to 70 years old
NCT03583203 
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Inclusion criteria:
• Individuals aged between 40 and 70 years• Confirmed diagnosis of bipolar disorder or schizophrenia according to the Diagnostic and Statis-
tical Manual of Mental Disorder IV (DSM-IV-TR)• Active smokers who currently consume at least 10 cigarettes a day, with a cumulative consump-
tion of 10 packets/year or more
Exclusion criteria:
• Previous respiratory diagnosis of asthma, cystic fibrosis, tuberculosis, simple chronic bronchitis,
restrictive pulmonary disease, or bronchiectasis• Acute respiratory symptoms• Heart disease or advanced oncological processes• Existence of a pathology that makes it advisable not to perform spirometry (recent pneumotho-
rax, recent thoracic or abdominal surgery, aortic aneurysm, unstable angulation, retinal detach-
ment, facial hemiparesis, or oral/dental problems)• Individuals who, due to their intellectual disability or mental pathology, do not understand or
cannot be forced to perform spirometry• Clinical instability with results of over 14 points on the Hamilton Depression Rating Scale, a Young
Mania Rating Scale of over 6, or a Positive and Negative Syndrome Scale of over 70
Interventions The primary objective evaluates the effectiveness of an intensive antismoking programme that in-
forms participants of their individual risk of lung damage and the possibilities of prevention. The
intervention group will undergo spirometry, and the presence and degree of respiratory obstruc-
tion will be assessed. Participants will be given individual information to generate a motivational
message about the possibilities of prevention, and the information will be maintained for 3 months
by sending text messages (SMS) to their mobile phones. This group will include personalised infor-
mation about lung damage. After evaluating their COPD, participants will be informed about its ex-
istence and staging. Depending on the damage found, the generation of motivation will focus on
the different prevention methods. Likewise, after the motivation level is set, participants will be of-
fered the option of treatment and regular follow-up. The intervention will be strengthened by mo-
tivational messages, half of which are linked to the possibilities of preventing respiratory damage,
sent to the participant's mobile phone via SMS during the 3 months after the face-to-face interven-
tion. Participants without mobile phones will receive a call on their phone to convey the same mes-
sages.
The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask,
Advice, Assess, Assist and Arrange).
Outcomes Primary outcome measures: smoking cessation (Time Frame: 12 months) self-reported abstinence
over the previous 7 days, confirmed by co-oximetry with expired CO < 10 ppm
Starting date 12 July 2018
Contact information Fernando Sarramea Crespo
fscferro69@gmail.com
Notes  
NCT03583203  (Continued)
 
 
Trial name or title Effectiveness of co-oximetry and minimum advice for smoking cessation in kidney transplant recip-
ients
Methods Randomised controlled trial (open, with blinded evaluation)
Pita Fernandez 2015 
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Participants 122 participants
Smoking kidney transplant recipients, in preparation stage, pre-contemplation, and contemplation
stage of change, who consent to participate
Interventions Intervention group: brief advice + exhaled CO measurement
Control group: brief advice for smoking cessation
Outcomes Smoking cessation at 6 and 12 months confirmed by nicotine test
Starting date 1 December 2012 (end date 31 December 2015)
Contact information Dr Salvador Pita-Fernández
Notes Study completed but data not published.
Author contacted but no answer received.
Pita Fernandez 2015  (Continued)
 
 
Trial name or title Clinical trial on the efficacy of exhaled carbon monoxide measurement in smoking cessation in pri-
mary health care
Methods Parallel randomised controlled trial with blind evaluation (single)
Participants 942 participants
Inclusion criteria:
• Smokers >= 18 years of age attended for any reason• Smokers in contemplation or pre-contemplation phase
Interventions Intervention group: brief advice plus exhaled CO measure
Control group: brief face-to-face antismoking advice from the physician during patient consulta-
tion
Outcomes Sustained abstinence (at 6 and 12 months) validated by urine cotinine test
Starting date 15 October 2010 (end date 15 October 2012)
Contact information Miss Joana Ripoll
jripoll@ibsalut.caib.es
Notes Study no longer recruiting, no data published.
Author contacted but no answer received.
Ripoll 2012 
CO: carbon monoxide
COPD: chronic obstructive pulmonary disease
EEG: electroencephalogram
NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
NRT: nicotine replacement therapy
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   All interventions
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Smoking cessation - feedback on
smoking exposure
5 2368 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.83, 1.21]
2 Smoking cessation - feedback on
smoking-related disease risk
5 2064 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.63, 1.01]
2.1 Genetic marker for cancer risk 3 1297 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.65, 1.10]
2.2 Genetic marker + CO 1 270 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.34, 1.17]
2.3 Genetic marker for risk of
Crohn's disease
1 497 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.32, 1.71]
3 Smoking cessation - feedback on
smoking-related harm
11 3314 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.99, 1.61]
3.1 Spirometry with or without lung
age
5 1728 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.83, 1.84]
3.2 CO and spirometry feedback 4 895 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.74, 2.18]
3.3 Carotid ultrasound 2 691 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.67, 3.66]
 
 
Analysis 1.1.   Comparison 1 All interventions, Outcome 1 Smoking cessation - feedback on smoking exposure.
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Audrain 1997 20/156 23/137 11.66% 0.76[0.44,1.33]
Brunette 2013 15/58 21/66 11.35% 0.81[0.46,1.42]
Jamrozik 1984 91/528 77/512 46.19% 1.15[0.87,1.51]
Sanders 1989 52/376 55/375 28.98% 0.94[0.66,1.34]
Shahab 2011 5/81 3/79 1.83% 1.63[0.4,6.57]
   
Total (95% CI) 1199 1169 100% 1[0.83,1.21]
Total events: 183 (Intervention), 179 (Control)  
Heterogeneity: Tau2=0; Chi2=2.93, df=4(P=0.57); I2=0%  
Test for overall effect: Z=0(P=1)  
Favours control 1000.01 100.1 1 Favours feedback
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Analysis 1.2.   Comparison 1 All interventions, Outcome 2
Smoking cessation - feedback on smoking-related disease risk.
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Genetic marker for cancer risk  
Hishida 2010 15/257 22/276 13.49% 0.73[0.39,1.38]
Ito 2006 58/341 67/356 53.4% 0.9[0.66,1.24]
Nichols 2014 10/36 12/31 11.44% 0.72[0.36,1.43]
Subtotal (95% CI) 634 663 78.33% 0.84[0.65,1.1]
Total events: 83 (Intervention), 101 (Control)  
Heterogeneity: Tau2=0; Chi2=0.58, df=2(P=0.75); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
   
1.2.2 Genetic marker + CO  
Audrain 1997 14/133 23/137 14.1% 0.63[0.34,1.17]
Subtotal (95% CI) 133 137 14.1% 0.63[0.34,1.17]
Total events: 14 (Intervention), 23 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
   
1.2.3 Genetic marker for risk of Crohn's disease  
Hollands 2012 9/251 12/246 7.57% 0.74[0.32,1.71]
Subtotal (95% CI) 251 246 7.57% 0.74[0.32,1.71]
Total events: 9 (Intervention), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
Total (95% CI) 1018 1046 100% 0.8[0.63,1.01]
Total events: 106 (Intervention), 136 (Control)  
Heterogeneity: Tau2=0; Chi2=1.37, df=4(P=0.85); I2=0%  
Test for overall effect: Z=1.88(P=0.06)  
Test for subgroup differences: Chi2=0.78, df=1 (P=0.68), I2=0%  
Favours control 1000.01 100.1 1 Favours feedback
 
 
Analysis 1.3.   Comparison 1 All interventions, Outcome 3 Smoking cessation - feedback on smoking-related harm.
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Spirometry with or without lung age  
Buffels 2006 20/102 19/113 11.3% 1.17[0.66,2.06]
Drummond 2014 0/24 1/26 0.58% 0.36[0.02,8.43]
Irizar Aramburu 2013 15/159 21/176 9.95% 0.79[0.42,1.48]
Parkes 2008 38/280 18/281 12.13% 2.12[1.24,3.62]
Segnan 1991 19/292 15/275 9.34% 1.19[0.62,2.3]
Subtotal (95% CI) 857 871 43.3% 1.24[0.83,1.84]
Total events: 92 (Intervention), 74 (Control)  
Heterogeneity: Tau2=0.07; Chi2=6.44, df=4(P=0.17); I2=37.88%  
Test for overall effect: Z=1.06(P=0.29)  
   
1.3.2 CO and spirometry feedback  
McClure 2009 40/267 35/269 15.7% 1.15[0.76,1.75]
Favours control 1000.01 100.1 1 Favours feedback
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Risser 1990 9/45 3/45 3.38% 3[0.87,10.36]
Sippel 1999 9/103 14/102 7.13% 0.64[0.29,1.4]
Walker 1985 10/32 5/32 5.29% 2[0.77,5.2]
Subtotal (95% CI) 447 448 31.5% 1.27[0.74,2.18]
Total events: 68 (Intervention), 57 (Control)  
Heterogeneity: Tau2=0.14; Chi2=5.7, df=3(P=0.13); I2=47.35%  
Test for overall effect: Z=0.86(P=0.39)  
   
1.3.3 Carotid ultrasound  
Bovet 2002 13/75 5/80 5.05% 2.77[1.04,7.41]
Rodondi 2012 66/267 59/269 20.15% 1.13[0.83,1.53]
Subtotal (95% CI) 342 349 25.2% 1.56[0.67,3.66]
Total events: 79 (Intervention), 64 (Control)  
Heterogeneity: Tau2=0.27; Chi2=2.97, df=1(P=0.08); I2=66.31%  
Test for overall effect: Z=1.02(P=0.31)  
   
Total (95% CI) 1646 1668 100% 1.26[0.99,1.61]
Total events: 239 (Intervention), 195 (Control)  
Heterogeneity: Tau2=0.05; Chi2=15.2, df=10(P=0.13); I2=34.2%  
Test for overall effect: Z=1.9(P=0.06)  
Test for subgroup differences: Chi2=0.23, df=1 (P=0.89), I2=0%  
Favours control 1000.01 100.1 1 Favours feedback
 
 
Comparison 2.   Multiple versus single measurement
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Smoking cessation 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Genetic marker + CO vs CO only 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Multiple versus single measurement, Outcome 1 Smoking cessation.
Study or subgroup Intervention Control Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.1.1 Genetic marker + CO vs CO only  
Audrain 1997 14/133 20/156 0.82[0.43,1.56]
Favours control 50.2 20.5 1 Favours intervention
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Comparison 3.   All interventions
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Spirometry and/or lung age 5 1728 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.83, 1.84]
1.1 Spirometry with lung age 2 611 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.62, 5.05]
1.2 Spirometry without lung age 3 1117 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.73, 1.48]
 
 
Analysis 3.1.   Comparison 3 All interventions, Outcome 1 Spirometry and/or lung age.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Spirometry with lung age  
Drummond 2014 0/24 1/26 1.53% 0.36[0.02,8.43]
Parkes 2008 38/280 18/281 27.49% 2.12[1.24,3.62]
Subtotal (95% CI) 304 307 29.02% 1.77[0.62,5.05]
Total events: 38 (Experimental), 19 (Control)  
Heterogeneity: Tau2=0.24; Chi2=1.18, df=1(P=0.28); I2=15.38%  
Test for overall effect: Z=1.07(P=0.28)  
   
3.1.2 Spirometry without lung age  
Buffels 2006 20/102 19/113 25.87% 1.17[0.66,2.06]
Irizar Aramburu 2013 15/159 21/176 23.17% 0.79[0.42,1.48]
Segnan 1991 19/292 15/275 21.94% 1.19[0.62,2.3]
Subtotal (95% CI) 553 564 70.98% 1.04[0.73,1.48]
Total events: 54 (Experimental), 55 (Control)  
Heterogeneity: Tau2=0; Chi2=1.06, df=2(P=0.59); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
   
Total (95% CI) 857 871 100% 1.24[0.83,1.84]
Total events: 92 (Experimental), 74 (Control)  
Heterogeneity: Tau2=0.07; Chi2=6.44, df=4(P=0.17); I2=37.88%  
Test for overall effect: Z=1.06(P=0.29)  
Test for subgroup differences: Chi2=0.91, df=1 (P=0.34), I2=0%  
Favours risk assessment 1000.01 100.1 1 Favours control
 
 
A P P E N D I C E S
Appendix 1. Specialized Register search strategy
For Cochrane Register of Studies
#1 patient education:EMT,MH,KW,TI,AB
#2 patient compliance:EMT,MH,KW
#3 patient counsel?ing:EMT,MH,KW,TI,AB
#4 persuasive communication:EMT,MH,KW
#5 spirometry:EMT,MH,KW,TI,AB
#6 respiratory function:EMT,MH,KW
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#7 bronchospirometry:EMT,MH,KW,TI,AB
#8 carbon monoxide:EMT,MH,KW,TI,AB
#9 (forced expiratory volume or forced expiratory flow):EMT,MH,KW,TI,AB
#10 FEV?:TI,AB
#11 obstructive lung disease*:EMT,MH,KW,TI,AB
#12 genetic testing:EMT,MH,KW
#13 genetic susceptibility:EMT,MH,KW
#14 genetic predisposition:EMT,MH,KW
#15 (genetic NEAR (test* OR risk*)):TI,AB
#16 biomarker*:EMT,MH,KW,TI,AB
#17 screening:TI,AB
#18 feedback:EMT,MH,KW,TI,AB
#19 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18
W H A T ' S   N E W
 
Date Event Description
26 March 2019 Amended Addition to acknowledgments
 
H I S T O R Y
Protocol first published: Issue 2, 2004
Review first published: Issue 4, 2005
 
Date Event Description
16 November 2018 New citation required but conclusions
have not changed
New searches run: 27 March 2018. Conclusions unchanged.
15 October 2018 New search has been performed Updated, 5 new studies included (1 with incomplete data), con-
clusions unchanged
20 August 2012 New citation required but conclusions
have not changed
Updated with 4 new included studies, conclusions unchanged
20 August 2012 New search has been performed Updated search run, 4 new studies included, text updated
28 January 2009 New citation required and conclusions
have changed
1 new study shows a significant effect.
27 January 2009 New search has been performed 3 new studies identified in update for Issue 2, 2009.
21 April 2008 Amended Converted to new review format
11 August 2005 New citation required and conclusions
have changed
Substantive amendment
 
C O N T R I B U T I O N S   O F   A U T H O R S
CC: (for 2019 update) screening search results, organising retrieval of papers, screening papers for inclusion, quality appraisal of papers,
data extraction, data management, data entry into Review Manager 5, data analysis and interpretation, writing to authors of papers for
additional information, update of the review.
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YM: screening search results, organising retrieval of papers, screening papers for inclusion, quality appraisal of papers, data extraction,
data management, data entry into Review Manager 5, data analysis and interpretation, writing the review, writing to authors of papers
for additional information.
JLB: (for 2019 update) conducted the GRADE evaluation and added the 'Summary of findings' table, and contributed to the writing of the
review.
BB: conception and design of the review, developing search strategy, screening papers for inclusion, quality appraisal of papers,
interpretation of data, methodological perspective, general advice on the review, securing funding.
JYC: (for 2012 update) screening papers for inclusion, quality appraisal of papers, data extraction, data management, data entry into Review
Manager 5, data analysis and interpretation, update of the review.
JC: conception and design of the review, developing search strategy, screening search results, screening papers for inclusion, quality
appraisal of papers, interpretation of data, clinical and methodological perspective, general advice on the review.
MRW: (for 2012 update) screening papers for inclusion, quality appraisal of papers, data extraction, data management, data entry into
Review Manager 5.
KS: (for 2019 update) screening papers for inclusion, quality appraisal of papers, data extraction.
RB : co-ordinating the review, conception and design of the review, data collection, developing search strategy and undertaking searches,
screening search results, organising retrieval of papers, screening papers for inclusion, quality appraisal of papers, data extraction, data
management, data entry into Review Manager 5, data analysis and interpretation, writing the review, writing to authors of papers for
additional information, providing a clinical perspective.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Following changes to the Cochrane Tobacco Addiction Group's recommended method of data analysis since this review was first prepared,
we have changed the way in which we summarise the eHects of treatment. From the 2009 update onwards, we use the risk ratio rather
than the odds ratio for summarising individual trial outcomes and for estimates of pooled eHect. Treatment eHects will seem smaller when
expressed as risk ratios than when expressed as odds ratios, unless the event rates are very low. For example, if 20 out of 100 participants
have quit in the intervention group, and 10 out of 100 in the control group, the risk ratio is 2.0 ((20/100)/(10/100)), while the odds ratio is
2.25 ((20/80)/(10/90)). While there are circumstances in which odds ratios may be preferable, there is a danger that they will be interpreted
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as if they are risk ratios, making the treatment eHect seem larger (Higgins 2011). We estimated a pooled weighted average of risk ratios
using a Mantel-Haenszel random-eHects method, with 95% confidence intervals.
From the 2019 update onwards, we decided to pool studies using similar biofeedback strategies even if they were performed in diverse
settings. Given the fact that there were more studies included than in previous reviews, we considered that the clinical heterogeneity was
acceptable even if the setting and staH were diHerent.
From the 2019 update onwards, we changed the 'Risk of bias' assessment from assessing blinding of participants, study personnel, and
outcome assessment (both performance and detection bias) to assessing outcome assessment (detection bias only) alone. This is because
interventions of this type cannot be blinded, and is in accordance with Cochrane Tobacco Addiction Group guidance.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Biofeedback, Psychology  [*methods];  Breath Tests;  Carbon Monoxide  [*analysis];  Genetic Predisposition to Disease;  Randomized
Controlled Trials as Topic;  Risk Assessment  [methods];  Smoking  [*adverse eHects]  [genetics]  [metabolism];  Smoking Cessation
 [methods]  [*psychology]  [statistics & numerical data];  Spirometry
MeSH check words
Adult; Female; Humans; Male
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